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ABSTRACT OF THE DISSERTATION
VCP: A Gatekeeper for Intracellular Proteopathic Seeding
By Jiang Zhu
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Professor Conrad C Weihl, Chair

Protein inclusions such as β-amyloid, tau, α-synuclein, and TDP-43 are considered the
pathologic hallmarks of many neurodegenerative diseases. These proteins are prone to
misfold, aggregate, and template new aggregates. Accumulating evidence suggests that those
proteins in their high-molecular-weight forms can serve as a "seed", spread through an
interconnected brain network, and induce new inclusions. Therefore, it is essential to
understand the mechanism of proteopathic seeding.
In this dissertation, we performed a whole genomic CRISPR-Cas9 KO screening to
identify gene modifiers of αS seeding. Within the screening, we found several hits of
endolysosomal function and trafficking, including VCP. VCP is a versatile protein required
for protein homeostasis. Mutations in VCP are associated with type 1 Multisystem
proteopathy (MSP1), whose patients can develop multiple neurodegenerative diseases with
proteopathic protein inclusions, including Frontotemporal dementia (FTD), amyotrophic
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lateral sclerosis (ALS), Parkinson and Alzheimer's. We validated that either VCP dysfunction
(inhibition or RNAi knockdown) or VCP disease mutations can exacerbate αS seeding in
both αS biosensor cells and hippocampal neurons, in which both VCP knockdown and VCP
mutation knock-in neurons show increasing αS aggregation following seeding. Additionally,
mice carrying a VCP disease mutation exhibit more αS aggregates than C57 control 90 days
after intrastriatal injection of αS pre-formed fibrils in vivo. We showed that VCP aggravates
endolysosomal membrane damage with the proteopathic seeds. Similarly, seeding activities
increased when we co-treated the cells with seeds and LLOMe, a drug specifically
permeabilizes the endolysosome. Previously, in our lab, we demonstrated VCP involved in
the autophagy-mediated clearance of damaged endolysosome, called lysophagy. Screening
different VCP cofactors, we identified that only lysophagy-related cofactor UBXD1 modifies
the α-synuclein seeding the same as VCP. We proposed that VCP might regulate αS seeding
via UBXD1-dependent lysophagy.
This dissertation also developed two novel TDP-43 seeding assays, which phenocopies
hyper-phosphorylated TDP-43 aggregations in patients. We observed the same protective
effect of VCP on intracellular TDP-43 seeding and tau. Overall, our results support VCP as a
gatekeeper for different intracellular proteopathic seeding in a merging pathway.
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Chapter 1: Introduction

1

1.1 proteopathic seeding and neurodegenerative diseases
Neurodegenerative diseases (NDD) are adult-onset disorders affecting more than 9
million American1. It includes Alzheimer's disease (AD), Parkinson's disease, Huntington
disease, Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), multiple
system atrophy (MSA), etc. Regardless of diverse phenotypes, NDDs are characterized by
progressive neuronal loss, which leads to neurological dysfunctions.

1.1.1 proteopathic seeding hypothesis
Despite their distinct clinic symptoms, most NDDs patients have protein aggregates as a
definitive feature. The major components are different from diseases – AD is remarked by Aβ
aggregates and tau tangles; Parkinson's and MSA accumulation α-synuclein positive
inclusions called Lewy bodies; Huntington is caused by polyQ aggregates; ALS can be
divided into different subtypes by the different types of proteins in inclusion (TDP-43 or FUS
or SOD1).

The proteopathic seeding hypothesis was proposed in the late 1990s, inspired by
infectious prions in prion diseases, since Aβ, tau, and other signatures in NDDs can convert
from their native form to amyloid β sheets and turn into insoluble fibrils, same as prions.
Numerous studies demonstrated that these amyloid forms could accelerate and template the
monomers to form new aggregates. Furthermore, injecting patients' brain lysates into naïve
animals can provoke disease-like symptoms and inclusion bodies2. Braak's studies identified
the different stages of aggregation in AD, Parkinson's, FTD, and ALS, suggesting the
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temporal-spatial propagation of those aggregates3,4. Fetal neurons transplanted to Substantia
Nigra (SN) of the Parkinson patients showed synuclein inclusion in the grafted tissues5. It
evidences the transformation of those proteins from one region to another in the human brain.
Together, scientists declared a proteopathic seeding hypothesis in NDDs and named those
infectious proteins as proteopathic proteins (also called prion-like proteins or prionids).

The proteopathic proteins usually have the following features:

1) Those proteins are native unfolded (α-synuclein and tau) or contain an unstructured region (TDP43)6, prone to aggregate.
2) The fibrillar or oligomeric(e.g., tau and Aβ) forms of those proteins can specifically template and
promote the fibrillization of its monomers6. (This process is called seeding. And the high-molecularweight species are named seed and recognized as seeding compatible.)
3) The aggregate or oligomer form of those proteins is neurotoxic 7–10.
4) The propagation of those protein aggregates (tau, α-synuclein, and TDP-43) can be closely related
to disease progression11.

Some proteopathic inclusions (e.g., synuclein and tau) can precede the first symptoms of
NDDs12 and propagate across brains as disease progress4. Previous research showed that
blocking the proteopathic intracellular seeding can prevent seed propagation, rescue neuron
loss, and benefit motor behaviors in mouse model13,14. Therefore, proteopathic seeding could
offer new therapeutic targets to a broader range of NDDs patients regardless of their genetic
backgrounds.

3

Of note, other pathological features including inflammation, mitochondria dysfunction,
and oxidative stress are shared in many NDDs as well, which are detailed reviewed
elsewhere15,16. Meanwhile, proteopathic protein might contribute to the diseases in other
aspects independent of aggregates and its seeding capacity, like TDP-43, which I will briefly
mention below. Furthermore, as the definition suggests, proteopathic proteins are prone to
aggregates, but not all aggregated proteins are proteopathic. Moreover, inclusion bodies in
NDDs can be highly diverse, deposit up to hundreds of different kinds of proteins17,18.
Finally, although my research focuses on proteopathic seeding in neurons, some evidence
implied the involvement of glia in seeding as well4,19.
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Figure 1. 1: increasing recognition on proteopathic seeding in literature.
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1.1.2 αlpha-Synuclein
αS (encoded by SNCA gene) is a 140 amino acid protein highly enriched in the neurons,
predominantly in the pre-synaptic terminal. αS locates at the reserved pools of the vesicle and
might function in synaptic transmission based on SNAC KO mice20. αS is composed of the
N- terminal domain, a non-amyloid-β component (NAC) domain, and a disordered Cterminal. It is unfolded monomer or multimers naturally, but upon seeding and pathological
conditions, αS is converted to oligomers and amyloid fibrils. αS is identified as the major
component of inclusions – Lewy bodies – in the neurons or astrocytes of Parkinson's Disease,
Diffuse Lewy body disease (DLB), multiple system atrophy (MSA), and REM sleep behavior
disorder (RBD). Meanwhile, SNCA mutations, duplication, or triplication of this locus are
associated with PD and MSA21.

The seeding capacity of αS is well characterized. Because of the disordered secondary
structure, αS fibril can seed monomers in vitro. Exposure of HEK 293 cells stably
overexpressing αS to αS fibrils or brain extract from PD and MSA patients can covert
monomeric αS into aggregates within 24 hours22. Likewise, adding αS fibril to the primary
cells (e.g., neurons23 and oligodendrocytes24) is sufficient to induce novel hyperphosphorylated detergent-resistant αS aggregates. This seeding event could happen
anterogradely and retrogradely in neurons25. The novel αS aggregate is seeding compatible as
well (called passage), which amplifies αS pathology22.
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Either inoculation of αS purified fibril or extraction from α-Synucleinopathy patients
into the brain can generate αS pathology in wild-type mice or monkeys. Regardless of
different injection sites (SN, olfactory bulb, or striatum), hyperphosphorylated αS inclusions
were observed from the proximal injection area to the more distal area in a time-dependent
manner26–29. The injected animal also exhibited a neuronal loss in SN and motor deficits.

Several pathways are known to affect the αS seeding process. Although αS monomer
can freely diffuse into the cell, αS fibril mainly takes up via endocytosis30. HSPG mediates
αS fibril via micropinocytosis and, in turn, affects seeding31. Alternatively, LAG3 and two
other transmembrane receptors were identified to selectively bind to αS fibril and take up αS
fibril via endocytosis. LAG3 deletion can alleviate αS neuron-to-neuron transmission and
reduce αS pathology and motor deficits in injection model32.

Once uptake, αS fibril predominantly localizes in the endo-lysosome. The role of
lysosomes in αS seeding is mysterious. Lysosome inhibition showed persistent αS fibril in
cells, implicate reduced degradation33. And knockdown of the lysosomal K+ channel
TMEM175 or drug inhibition of lysosome (CHQ) enhanced the seeding efficiency in primary
neurons34,35. Permeabilizing endolysosome by LLOMe raises αS seeding efficiency in Jiang
et al.'s study36. It is consistent with my results in cells and primary neurons. In contrast,
lysosome inhibition and knockdown of core lysosomal protein showed a decrease in αS
seeding37. Those contradictive studies might suggest dual roles of the lysosome in αS seeding
(discuss later).
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Several polyphenols (EGCG, brazilin, resveratrol, etc.) can antagonize the fibrillation of
αS38. Brazilin can biochemically ameliorate αS fibrilization and protect neurons from cell
death39, consistent with our result of EGCG on the αS biosensor line (data not shown).
Meanwhile, chaperone/co-chaperone, like DNAJB640 and Hsp11013, prevents αS seeding
probably by fibril disassembly41.

αS aggregates might be released extracellularly from dead neurons. However, it cannot
explain the fast propagation and wide spreading of αS in patients and mouse injection
models. Moreover, Ulusoy et al. showed αS propagation independent of neurodegeneration in
rat42. Although αS contains no secret signal, αS is found in the CSF of healthy control and
synucleinopathy patients43. αS aggregates can be secreted extracellularly by exosome44. In
parallel, exosomes isolated from brain extract or the CSF of DLB patients enrich αS are
seeding capable45. Besides, αS fibril and TDP-43 can transfer in tunneling nanotubes between
cells46,47.

Apart from the known pathways in seeding, other orphan genes were found, whose role
in seeding is still enigmatic or controversial. Three parkinsonism risk genes – LRRK248,49,
GBA49 and APOE450 – modulate αS seeding efficiency in both cell and mouse models. Both
LRRK2 and GBA modulate total αS expression49, and LRRK2 contributes to many aspects of
the lysosome-autophagy pathway51, which is essential for protein homeostasis and aggregates
clearance. APOE4 links with earlier onset52 and faster cognitive decline of PD 50. However,
the molecular mechanism of these effects needs further investigation.
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1.1.3 TDP-43
TAR DNA binding protein 43 (TDP-43) is a highly conserved DNA/RNA binding
protein. TDP-43 is ubiquitously expressed in many tissues. It contains an N-term region (aa
1–102) with nuclear localization signal (NLS, aa 82–98), two RNA recognition Motifs RRMs
(aa 104–176 and aa 192–262), a nuclear export signal (NES, aa 239–250), followed by an
unstructured C-terminal region (aa 274–414) with prion-like glutamine/asparagine-rich (Q/N)
domain (aa 345–366) and a glycine-rich domain (aa 367–414). By binding to specific RNA
via RRM, TDP-43 can involve in many RNA metabolisms, including transcription, premRNA splicing, mRNA transport, translation, microRNA and long non-coding RNA
processing, stress granules, etc53. TDP-43 normally acts in the nucleus as a dimer but can
translocate to cytoplasm or mitochondria. For instance, TDP-43 can be recruited to stress
granules under stress exposure, binds to RNA, and regulates transcription. This regulation
can be crucial for some cellular events, like muscle regeneration54. Loss of TDP-43 in
neuronal-like cells (Neuro-2A) blocks neurite outgrowth and induces apoptosis55, and
homozygous depletion of TDP-43 in mice cause early embryonic lethality56.

In 2006, TDP-43 was identified as the main component of tau negative inclusion bodies
in the spinal cord of both sporadic and familial ALS and the cortex of FTD. The insoluble
TDP-43 is ubiquitinated, hyperphosphorylated, cleaved into a C-terminal fragment, and
abnormally present in the cytosol. Moreover, studies have found TDP-43 positive inclusions
in many other NDDs, including 50% Alzheimer's, 50-60% DLB, and almost 100%
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Huntington's. Besides, TDP-43 is a less common gene cause of ALS, accounting for 2%
fALS.

Similar to Aβ, tau, and αS, TDP-43 behaves as a proteopathic protein. First, it is the
major component of inclusion bodies found in 97% of ALS and 45% of FTD. Second, similar
to other proteopathic proteins, its unstructured Q/N rich region is prone to aggregate53,57. In
addition, most of the TDP-43 mutations identified in familiar ALS-FTD patients are located
at C-terminal, and many mutations display increased insolubility, together with higher
cytotoxicity compared with WT TDP-4358–60. The full-length TDP-4361 or its fragment60,62
can self-template and specifically promote the fibrillization of TDP-43 monomers in vitro.
Third, although TDP-43 seeding is less easy than αS, Multiple studies demonstrated TDP-43
seeding both in vitro and in vivo. Applying either purified TDP-43 fibril63 or patients' extract
with insoluble TDP-4364 is sufficient to generate insoluble phosphorylated and ubiquitinated
TDP-43 aggregates, which mimics TDP-43 inclusions in patients. The TDP-43 aggregates
localize with Multivesicular bodies and can freely transmit between cells64,65. Injecting FTD
patient extracts with insoluble TDP-43 enables to induce new aggregates and spread across
the brain neural network with time on mice66. Wang's group67 recently found TDP-43 seeding
events after motor cortex injection with purified recombinant TDP-43 fibril in a timedependent manner. Those injections also accelerated ALS-like symptoms (motor defect and
electrophysiological abnormalities) compared with vehicle controls. However, the pitfalls of
both studies are using TDP-43 transgenic mice as mouse model, whereas WT TDP-43
overexpression used in studies above is sufficient to accumulate TDP-43 cytoplasmic
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inclusion and generate the neuronal loss, memory loss, and motor dysfunctions at a later
stage68,69. And the severity of ALS-like symptoms is correlated with the dose of TDP-43
expression68. Forth, although under dispute, several studies suggest that oligomer and
aggregate form of TDP-43 is cytotoxic61,62,70. Intrahippocampal injection of TDP-43
oligomers drove local neuronal loss at CA1 region61. Finally, TDP-43 pathology spreads
sequentially in stages in ALS and FTD. The sequences of TDP-43 deposits are associated
with functional loss and disease progression71. In AD, TDP-43 burden is paralleled with
cognition impairment and memory loss, and regional atrophy after control for age, APOE,
Braak's stage, and other AD pathology72. Therefore, decoding the mechanism of TDP-43
seeding and spreading is an essential aspect of TDP-43 pathology.

Figure 1. 2: scheme of TDP-43 intracellular seeding and propagation.
It is partially adapted from ref 73 the brain anatomy comes from ref 3, the figure is made via
Biorender.
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1.1.4 other proteopathic proteins
Besides α-Synuclein and TDP-43, Aβ, tau, etc., are also considered as proteopathic
proteins. While polyQ, SOD1, TIA-1, FUS, and desmin show some seeding capability. The
evidence of their seeding property is summarized in Table 2. Of note, proteopathic proteins
are not only limited in the brain but other tissues, like the muscle. For example, TDP-43
inclusions have been found in the muscle of MSP and several different myopathies58,74. Like
TDP-43, Desmin, an intermediate filament protein with two amyloidogenic regions, is the
principal inclusion component in myofibrillar myopathies. Its mutations can lead to Eichsfeld
type congenital muscular dystrophy75. Our group found that WT Desmin monomer can selfassemble into seeding compatible fibril in vitro, accelerating further fibrillation. This desmin
fibril showed increased myotoxicity in vitro76.
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Table 1. 1: summary of properties of proteopathic proteins. It is partially adapted from ref 2
Misfolded protein

Human diseases

Prion-like properties in vitro

Prion-like properties in vivo

Strains

associated

neurotoxicity
Seeding

β-amyloid
Tau

AD
FTD-Tau, AD,

Induced

Yes
Yes

77

87,88

Propagation
Yes
Yes

Seeding

78,79

87,89,90

Yes

80–82

Yes

91–94

Propagation
Yes83,84
Yes

90,93–97

Yes82,85,86
Yes

98

Not yet
Not yet

PSP, AGD, PiD,
CBD
α-Synuclein

PD, LBD, MSA

Yes22

Yes44

Yes26–28

Yes26–28

Yes99–102

Yes (in
vitro and in
vivo)25,27,103,104

PolyQ

HD/SCA

TDP-43

ALS, FTD

SOD1

ALS

FUS
C9ORF72

ALS
ALS, FTD

Yes105
Yes

66,107

Yes108–111

Yes106

Not done

Yes

Yes

66,67

Not done
Yes

66,67

Not done
Yes

54

Not done
Yes (in vitro64)

Yes108,110,112

Yes113

Yes113

Not done

Yes (In vivo)

Yes

114

Not done

Not done

Not done

Not done

Not done

Yes

115

115,116

Not done

Not done

Not done

Yes (in vitro117,118)

Yes

associated
dipeptide
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1.2 Multisystem proteinopathy & VCP
1.2.1 VCP
Valosin-containing protein (VCP/p97, also called cdc48 in yeast), is an abundant AAA+
ATPase, conserved across species. VCP is widely expressed in many organs and tissues (e.g.,
muscle, brain, bone, liver, etc.) for various cellular activities, including cell cycle, DNA
repair, ER-associated degradation (ERAD), stress granule dynamics, autophagy, etc119. VCP
is composed of an N terminus (aa 1-187) followed by two ATPase domains, D1 (aa 209–460)
and D2 (aa 481–763) and C terminus (aa 764–806). VCP usually forms a homozygous
hexamer like a ring and unfolds or segregates its substrates fueled by ATP hydrolysis120.

VCP diverse cellular functions are mainly achieved by binding to different cofactors at
N- or C-terminal and recruiting different substrates. To date, more than 30 proteins have been
identified as VCP cofactors, and the number keeps increasing (the cofactors were reviewed in
ref 119). UFD1-NPL4 is the best studied VCP cofactors so far. UFD1-NPL4 facilitates the
disassembly or degradation of lysine 48-linked ubiquitin chains (K48) tagged proteins on the
membrane or within a large subunit. This UFD1-NPL4-VCP complex is required for many
VCP-mediated cellular functions. For example, in ERAD, Ufd1-Npl4 recognizes misfolded
proteins in the lumen and assists them to translocate through the central pole of VCP to
proteasome degradation in the cytosol; upon DNA double-strand break, UFD1-NPL4-VCP
complex recognizes and extracts K48 labeled Ku80, which releases chromatin and propels
DNA break joins121. Similarly, this complex can target other substrates such as IkBa, Aurora
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B, and Nrf1 to regulate NF-kB activation122, mitosis123, and homeostatic response124,
respectively.

VCP can impact endo-lysosome trafficking and autophagy-independent of Ufd1 and
Npl4. VCP localizes at endosome. Either VCP knockdown or VCP ATPase inhibitors showed
enlarged endosome and defect on end-lysosome fusion125,126. It is consistent with rimmed
vacuoles found in MSP1 patients' muscles. Research suggested that this VCP function is
mediated by cofactor UBXD1 binding to ubiquitinated CAV1126,127. In autophagy, doublemembrane vesicle engulfs selective cargos or cytoplasmic components and degrade them by
marge with the lysosome. VCP siRNA knockdown exhibits increased autophagy influx and
immature autophagosome128,129. The molecular mechanism of VCP in autophagy remains
unclear. VCP-Ataxin-3 can stabilize Beclin-1 and promote autophagy initiation130. However,
the immature autophagosome by VCP knockdown suggests VCP involvement in the
downstream autophagy process as well. One candidate cofactor for this process could be
UBXD1, a cofactor that binds to VCP exclusively to Ufd1 and Npl4120, proving to regulate
vesicle trafficking and sorting131. Furthermore, the VCP-UBXD1 complex has been found
essential for selective autophagy of large organelles such as damaged lysosome and
mitochondria, called lysophagy and mitophagy, respectively132,133.

1.2.2 Multisystem proteinopathy
In 2001, Kovach et al. first identified VCP mutations with a unique dominant
syndrome—inclusion body myopathy associated with Paget disease of bone and
frontotemporal dementia (IBMPFD), which affects muscle, bone, or brain134. Among all
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patients, ~90% have myopathy, half receive Paget disease of bone (PDB), 30% develop
frontotemporal dementia (FTD), whereas ~10% get fALS135 and a few other sporadic
phenotypes. Despite different types of tissues affected, one common feature is ubiquitin and
TDP-43 positive inclusions and rimmed vacuoles136. With the growth of exon sequencing in
clinics, VCP mutations have been identified in other discrete diseases in the last decade. For
example, several known VCP mutations were reported in Parkinsonism patients with αsynuclein-positive Lewy bodies in S. Nigra. Parkinsonism symptom can exist alone or
proceed IBMPFD137–139. Furthermore, in 2020, Lee's group identified two independent
families with new heterozygous mutation (D395G) that caused AD with tau tangles and
empty vacuoles in the absence of other proteopathic proteins, including TDP-43 and αsynuclein. This new mutation enhances the tau seeding efficiency in the tau overexpressed
HEK 293 cell line and mice with tau fibril injection140. According to the diversity of affected
tissues and diseases, those VCP caused conditions should be better referred to as type1
Multisystem proteinopathy (or MSP1, OMIM #167320). MSP1 is an adult-onset disease,
with the onsets at 42 for muscle and bone or 56 for FTD on average135. Other genes cause
MSP, including HNRNPA2B1, HNRNPA1, SQSTM1, MART3, OPTN, etc141. Distinct from
other diseases, MSP shows high variability, even carriers within the same family can exhibit
mosaic symptoms.

Due to the complexity of VCP protein function, the mechanism of VCP medicated MSP
is still controversial. Most VCP mutations exhibit comparable VCP protein expression level,
hexametric conformation, and normal or even higher ATPase activities142,143 (except
D395G140). However, no clear correlation between ATPase activity and pathological severity
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from different mutations has been found. Meanwhiles, our heterozygous knockout mice,
showed no distinct phenotypes in both the muscle144 and the brain145 by 12 months of age.
Hence, MSP1 is not due to the haploinsufficiency of VCP protein. Meanwhile, VCP
homozygous knockout mice are embryonic lethal146. Given the late onset of the MSP1, the
dysfunction of VCP mutations is not due to early embryonic development. Intriguingly, VCP
inhibition in Drosophila can alleviate some pathologies of VCP mutations, which supports a
gain of toxic function147. Other research using VCP knockdown and VCP inhibitors
phenocopied VCP disease mutations and MSP1 patients.

Given the proteopathic protein aggregation (TDP-43, tau, or αS) in MSP1, researches
focus on protein homeostasis on VCP mutations. ERAD helps the clearance of misfolded
proteins and plays an essential role in protein quality control. Some early studies discovered
the persistence of ERAD substrate ΔF508-CFTR in cells with VCP disease mutations142.
While Tresse et al.'s study showed VCP disease mutations have no changes in proteasome
degradation and ERAD activities using UbG76V and CD3δ as substrate, respectively126,129. In
contrast, autophagy is an alternative protein clearance machinery, especially for large
aggregates. Rimmed vacuoles in MSP1 patients' muscles are enveloped with doublemembrane vesicles and stained positive with autophagy markers LC3 and p62128.
Overexpressing VCP mutations showed increased autophagy flux (denoted by LC3 II/I), the
immature autophagosome, and delayed autophagy clearance128,129. This is in accordance with
some other MSP genes, such as SQSTM1 and OPTN, which are known as autophagy
adaptors141. Besides, overexpressing VCP disease mutations leads to the accumulation of
large polyQ80 inclusions, which fail to merge to autolysosome markers and delay in
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clearance in vitro148. Proteomic studies on VCP binding protein found VCP disease mutations
specifically decrease binding with cofactors UBXD1 and PLAA, but increase with Ufd1,
Npl4, and p47126,149,150, which indicates selective defect on the autophagy-related pathway.
VCP disease mutations mimic the effects of VCP siRNA and UBXD1 siRNA on lysophagy
and mitophagy128,129. UBXD1 N-terminal can stabilize VCP, and its binding reduces VCP
ATPase activity by 41% in vitro assay151. This imbalance towards Ufd1-Npl4 might explain
increased ATPase activity seen with some VCP mutations.

Besides, researchers also studied mitochondria since VCP mutations selectively affect
high energy expenditure tissues – muscle and brains. VCP mutations impede mitochondria
morphology clearance152, decrease mitochondrial membrane potential and ATP production153.
VCP might be involved in multiple aspects of mitochondria. VCP can surveille the outer
mitochondrial membrane (OMM) protein quality and translocates those proteins via the
UFD1-NPL4 proteasome pathway, called MAD154. Degradation of OMM proteins like Mfn1
and 2 upon depolarization damage leads to fission and mitochondria fragmentation155. At the
same time, VCP-UBXD1 can be recruited to damaged mitochondria marked by Parkin for
mitophagy (selective autophagy of mitochondria)156. The MAD and mitophagy might
interconnect, as Mfn2 degraded via MAD upon damages are ubiquitinated by PARKIN/PINK
and antagonizes mitophagy157.

VCP mutations can also impact stress granules dynamics. VCP mutations resulted in
constitutive stress granules158 and delayed disassembly after arsenite washout159. TDP-43, the
component of inclusion in MSP1, is also recruited to stress granules under stress conditions.
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In concert, MSP can be caused by mutations on many RNA-binding proteins, such as
HNRNPA2B1, HNRNPA1, and TIA-1, which are components of stress granules141.
However, the exact role of VCP in stress granules is still indefinite.

1.3 screening method and CRISPR
1.3. 1 screening methods
Genetic screens aim to link genotypes to phenotypes in high throughput assays.
Mutagenesis screen on the model organism is the first approach for screening done by Nobel
laureates Christiane Nüsslein-Volhard and Eric Wieschaus. DNA mutations are generated by
exposure to mutagens, the strains are selected with desired phenotypes, and finally, uncover
the mutations in those chosen strains. However, the effect of those random mutations is not
predictive. In parallel, the point mutations and affected genes are always not mutually
exclusive. This leads to incomplete coverage of the genome, high off-target effect, and
moderate repeatability. Additionally, sequentially phenotype selection is usually laborintensive and inefficient. Therefore, this forward screening method, including the
mutagenesis screen, is now largely replaced.

Scientists recently performed screening using full sequenced libraries with known
genetic targets. There are three elements of a functional screen: perturbation, model, and an
assay/readout. By type of perturbation, screens can be classified as the Open Reading Frame
(ORF) screen, the RNA interference screen, or the CRISPR-Cas9 screen. ORF screen is a
gain of function screen achieved by overexpressing ORFs from a cDNA library, usually in an
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arrayed format. The ORF of each gene is relatively long and less faithful160,161. Now ORF
screen is largely taken over by the CRISPRa screen (mentioned later). RNAi (using either
siRNA or shRNA) targets at transcription level since it might cause incomplete protein
depletion and have high off-target effects. CRISPR-Cas9 system-induced double-strand DNA
breaks (DSB) at the targeted sequence and induces frame-shift or deletion via NHEJ (discuss
more in the next section)162.

In parallel, the library can be either arrayed or pooled. In an arrayed screen, assays are
done in multiple-well plates, and each well has a different perturbation. The arrayed screen
provided direct genotype-phenotype correlation. However, it needs an automated platform for
large-scale cell culture and assay readout. In comparison, the pooled screen combines all the
perturbations together in a single batch, selects desired cells from the mosaic population by
their phenotypes, and then recovers the perturbation by NGS. Although the paracrine
signaling effect might influence the result of cells as a pool, The pooled screens still take
advantage over the arrayed based on the low cost and labor163.

1.3.2 unbiased screening on α-synuclein
The first αS screen was done in the yeast model since overexpressing human WT or
mutated αS in yeast inhibits the growth in a dose-dependent manner164. It offers a distinct
readout for screening. All genetic screens on αS are summarized in Table 1.2.

Although those screens broaden our knowledge of the nature of α-synuclein, some
pitfalls of the current screening are worth highlighting. First, early screens mainly were done
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in yeast or C elegans, which have only ~30%165 and ~40%166 homolog to the human genome.
This hinders the conclusion transfer to the disease mechanism in humans. Second, limited by
the volume of the library, some early screens are not really "unbiased". For instance, a
selection of PD-related genes or vesicle-related genes167,168 was picked as the total pool,
which has been documented associated with αS. This might contribute to a high possibility of
hits but low success in secondary validation. Meanwhiles can give rise to the missing genes
with a moderate effect on the readout. Hence, we need to alert the conclusion, especially the
pathway enrichment. Some pathways (e.g., vehicle trafficking) might be overscored because
of library selection. Third, in most of the current αS screens (except 168, 169, and 170), the
readout is based on observation and selected by researchers (e.g., more aggregate in worm
muscle wall or more colonies in yeast). It is labor-intensive and relatively subjective.

In addition, we need to think prudently over the readout for each screen. For example,
the cell survival in yeast (Ref 171, 172, 173, 174, 175, 176, and 129) is an indirect measurement of αS
expression. Alongside, other "essential" genes involved in cell survival might be picked by
the screens independent of αS level. Similarly, in the screen for αS oligomerization (ref 168),
some hits alter the readout signal merely by changing αS expression instead.

1.3.3 CRISPR-cas9 and pooled screening
Cas proteins are DNA endonucleases that can induce DSB guided by a short RNA
complement. It is a bacterial defense mechanism against phage infection found in bacteria.
Given the repeating sequences in bacteria, the system is named CRISPR (clustered regularly
interspaced palindromic repeat)-Cas. The CRISPR loci are intercalated with DNA fragments

21

from invaders, which can transcribe into RNA to guide the DSB as adaptive immunity.178 The
DSB will be repaired by Non-Homologous End Joining (NHEJ) or Homology-Directed
Repair (HDR) with the template. NHEJ is error-prone (insertion or deletion) and results in
gene deficit (KO) due to nonsense-mediated mRNA decay163. The short RNA, termed
CRISPR RNAs (crRNAs) or guide RNA, is effective as short as 20 nt179. Scientists first
successfully harnessed this CRISPR- Cas system to target gene editing with artificial
designed guide RNA in mammalian cells in 2013180,181. Cas9 from Streptococcus pyogenes
(SpCas9) is picked for gene editing since Cas9 can perform endonuclease activities at guide
RNA complemental site adjacent to a unique PAM sequence (NGG) downstream solely
without other endonucleases. The simplicity and flexibility of this two-component geneediting system enable scientists to study gene function on a large scale. The very first
CRISPR screens were done by Feng Zhang's and Eric Lander's groups in 2014182,183. To date,
more than 1500 screens184 have been done so far in yeast, immortalized cell lines, primary
cell culture, and even in animals 185–188. The pooled library usually contains 4-10 different
guide RNAs for each gene and abundant non-targeting guide RNAs as scramble controls.
And generally more than 500 copies of the cell for each gRNA to minimize systematic false
positive or negative163.

Typically, the CRISPR pooled screening includes the following steps163:

Step 1: cell preparation. Deliver cells with both Cas9 and gRNA library and maintain under
antibiotic selection for gRNA. Low MOI (usually <0.3) for gRNA is used to ensure most
cells get no more than one gRNA.
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Step 2: collect cells under selection. The simplest readout is the cell survival/ proliferation.
Cells with gRNA KO of essential for survival or cell cycle are deprived with time. Those
gRNAs will be identified when comparing the group of cells at early time points to that at
late time points. Similarly, based on the cell survival under a particular treatment, researchers
can identify genes for drugs resistance in cancer research, cytokines response in
inflammation, cell differentiation, or pathogen resistance for infectious diseases185,189.
Beyond that, some biological phenotypes can be captured with fluorescent reporter and
FACS. For example, to study the gene modifiers for a protein, researchers can make a
reporter line with the fluorescence tagged protein of interest and sort cells with low and high
fluorescence signals by FACS (e.g., ref 170 and 190).

Step 3: sequencing. In each group, gRNA is PCR amplified from DNA extraction and is
subject to Next Generation Sequencing separately.

Step 4: data analysis. The raw sequencing data represent gRNA abundancy in each group.
Nowadays, algorithms were built to identify genes responsible for the selection in Step 3.
Those tools always combine the effects of each gRNA that targets the same gene upon the
treatment and are normalized to non-targeting gRNA controls.

Step 5: Validation. It is performed in multiple ways using sub-library, other models, different
perturbation and assays, etc. The goal is to show the effectiveness of the screens and narrow
down hits to genes of interest.
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Besides traditional KO screening, the CRISPRa/i system is invented with endonucleasedeficient Cas9 fused to transcriptional enhancer or repressor. It empowers transcriptional
regulation of targeted genes without DSB. CRISPRa now substitutes ORF screens for gainof-function screens. Additionally, researchers introduced point mutations via HDR to conduct
CRISPR cas9188,191 mutagenesis screening, which can solve the variants of uncertain
significance within genes or genome.

CRISPR pooled screens override other screening methods due to this high throughput,
the versatility of library design, relatively low off-target effect, and low cost and labor.
Despite the advantage, there are systematic drawbacks of the CRISPR pooled screening.
First, Like other gene-editing using complemental pairing, CRISPR has an off-target effect.
However, it is minimized with increasing knowledge on the mechanism of the CRISPR-Cas9
system. Better in silico prediction generates more precise guide RNA design192,193.
Meanwhile, engineered Cas9 and other Cas proteins were innovated with higher fidelity like
Cas12a 163. Second, researchers might lose essential genes in their pool for a long-term
screen, as those genes are unfavored in proliferation163. Third, restricted by the large
coverages needed for the CRISPR screen (usually more than 500 copies per perturbation), the
cells can only be sorted and selected to a limited number of groups. The list of hits is not
weighted according to the readout. Genes moderately and highly regulate the readout might
be enriched in the same group. Therefore, the top hits from screening might not induce the
biggest effects in many cases. Some attempts are made to solve this problem. One is to
incorporate in situ sequencing, optic phenotypes, and automatic microscopy with CRISPR
screening, which enables phenotype-genotypes correlation in each gene with their readout
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one by one (e.g., ref 194). Forth, the false positive may occur when CRISPR-cas9 targets high
copy number genes, like oncogenes or repeated regions in high ploidy cancer cell lines163.
Finally, like other pooled screens, the application of CRISPR screens is restricted by limited
phenotype to readout other than cell survival and resistance to a certain treatment. The
fluorescent reporter is one direction and brings in some success. However, it is incapable of
sophisticated phenotypes, like mislocalization or morphology changes. A recent attempt is
applying an automatic microscope, AI algorithm, and photoactivatable fluorescent protein
into the screening. In brief, the pooled cells are automatically imaged, and cells with want
phenotypes are picked photo-activated and then selected by flow sorting. Those more
complicated screens require more effort to build and test and might introduce false alarms at
the same time (e.g., ref 195 and 196 ).

CRISPR functional screening used in NDDs is nascent. Besides the synuclein expression
screens I mentioned before, two group screens for the modifier of the expression level of
SQSTM1 and PARKIN, the gene associated with ALS and Parkinson's, respectively. Aaron
Gilter's group identified the essential role of ER stress components in neuronal survival under
dipeptide-repeat (DPR) proteins treatment by screens for DPR resistance197. As mature of
CRISPR techniques and the build-up of reporters, these screening methods can accelerate the
research in NDDs in the future.
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Table 1. 2: unbiased genetic screens on α-synuclein
model

library

readout

Yeast

4850 deletion haploid

Cell growth

overexpressing

mutation strands

affected by αSyn

human WT αSyn

primary screening result

follow-up

results
86 genes aggravate αS induced

Ref.
171

toxicity in yeast.

expression

Yeast expressing

Overexpression of

Cell growth

34 and 20 genes reduced

Validation in Drosophila,

the ER-Golgi transport gene,

WT αSyn-YFP

3000 randomly

affected by αSyn

and enhanced αSyn

C. elegans, and rat

YPT1 (ortholog of Rab1)

under a galactose

selected ORFs from a

expression

toxicity. Vesicle-mediated

midbrain primary

expression mitigates αSyn-

promoter

genome-wide

membrane trafficking

cultures

induced cell death.

collection

genes were enriched.

Yeast expressing

Overexpression of

Cell growth

55 suppressors and 22

A computational

Identification of 106 proteins

αSyn-YFP under a

5500 randomly

affected by αSyn

enhancers of a-syn toxicity

approach to identify

that were linked between

galactose promoter

selected ORFs in

expression

connectors between yeast

genetic hits and differentially

yeast strains (85% of

genetic screening and

expressed genes, not identified

the genome)

transcription data

by either of the individual

172

173

approaches. Ubiquitindependent protein degradation,
cell cycle regulation, and
vesicle-trafficking pathways are
overrepresented.
Primary screening in Ref

173

Validation in C. elegans

PARK9, PLK2, and PDE9A

and rat midbrain primary

(homolog of YPK9, PLK2, and

cultures.

Pde2 in humans) protect DA
neurons from αSyn-induced cell
death in both models. PARK9 is
a PD gene that protects cells
from Mn2+ exposure.
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174

Yeast expressing

CRISPR-aCas9 with

Cell growth

two gRNAs suppressed αS

Transcription analysis to

DJ-1, ALS2, GGA1, and

αSyn-YFP under a

randomized gRNA

affected by αSyn

toxicity

identify gene targets of

DNAJB1 protected cells from

galactose promoter

library

expression

the gRNAs. Promising

αS toxicity in both yeast and

gene targets were further

SH-SY5Y models.
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validated in yeast and
differentiated SH-SY5Y
cells expressing human
WT αSyn
Yeast expressing

High copy yeast

Cell growth after

YPP1 suppressed lethality

Screen YPP1 interactors

Class E VPS genes

A30P mutated αSyn,

genomic library

additional

of A30P but not WT and

overrepresent for A30P αSyn

challenged with

(overexpressing yeast

challenges with

A53T under ROS.

induce ROS increase.

H2O2 in yeast

chromosome

H2O2

176

fragment)
Yeast expressing

High copy yeast

Cell growth after

~100 protected plasmids

testing ROS signal

5 selective hits, ARG2, ENT3,

WT- αSyn,

genomic library

additional

recovered

overexpression and

IDP3, JEM1, and HSP82,

challenged with

(overexpressing yeast

challenges with

deletion strains

suppressed ROS signal with

H2O2

chromosome

H2O2

129

overexpression and increased

fragment)

with deletion.

C. elegans

RNAi of a selection of

Aggregation of

20 genes enhance αSyn

Overexpression of seven

5 genes protected DA neurons

expressing human

868 genes associated

αSyn-GFP in body

aggregates at late larva

hits, survival of DA

from αSyn toxicity in C.

αSyn-GFP in body

with PD, involved in

wall cells

stages.

neurons in C. elegans

elegans, including worm

wall cells

protein degradation

homolog of ATG7, VPS41, and

and interactors of

SEC22. Both VPS41 and

these

SEC22 encode the protein for
vesicle trafficking.
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167

C. elegans

whole genomic RNAi

amount of αS

80 strains enhanced αS

expressing human

library (Ahringer)

inclusions at adult

aggregation. Quality

αSyn-YFP in body

covered 87% of C.

stage

control and vesicle-

wall muscle cells

elegans genes

198

trafficking genes expressed
in the ER/Golgi complex
and vesicular
compartments were
overrepresented

Human H4

Lentiviral mediated

αSyn

4 genes encoding Rab

total αS expression, Cell-

All hits except RAB39B αS

neuroglioma cells

RNAi library of 1387

oligomerization

proteins (RAB8B,

to-cell trafficking, and αS

aggregation. Silencing of

Bimolecular

genes involved in

measured by

RAB11A, RAB13, and

aggregations and

RAB8B, RAB13, or SYTL5

expressing N-

membrane trafficking

fluorescence

RAB39B) and 5 genes

cytotoxicity with

increases aSyn cell-to-cell

terminal GFP and C-

and signal

complementation

encoding kinases or signal

silencing of selected hits.

trafficking. RAB8B silencing

terminal GFP halves

transduction related

transduction proteins

increases total αS level,

linked to αSyn

pathways

(CAMK1, DYRK2,

aggregations, and cytotoxicity.

168

CC2D1A, CLK4, and
SYTL5) were identified
human HTB-186 cell

shRNA library

with DsRed-IRES-

targeting 7787

SNCA- EGFP

druggable genes

αSyn level

60 genes modified αS

Validated αS expression

10 genes regulated αS induced

level.

of 33 αS suppressors by

viability in the Drosophila

Western blot. Valid

model. 6 out of 10 selective

candidates were tested in

hits were validated whose

Drosophila, hESC-

knockdown ameliorated αS

derived neurons, and

expression in both hESC-

mouse brain

derived neurons and mouse
brain.
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169

HEK293T cells with

CRISPR-Cas9

αSyn degradation

Identifies proteasome

tetracycline-

genomic-wide library

under Canthin-6-

components -- PSMA1,

inducible α-syn-

(GeCKO)

one measured by

PSMA6, PSMA7, and

GFP level

PSMD1 regulates Canthin-

EGFP

6-one induced αSyn
degradation

Table partially Adapted from ref 199.
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Chapter 2 VCP protect against proteopathic
seeding
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This chapter is adapted from VCP protects neurons from proteopathic seeding

Jiang Zhu, Sara Pittman, Dhruva Dhavale, Rachel French, Jessica N. Patterson, Mohamed
Salman Kaleelurrrahuman, Yuanzi Sun, Jaime Vaquer-Alicea, Gianna Maggiore, Christoph S.
Clemen, William J. Buscher, Jan Bieschke, Paul Kotzbauer, Yuna Ayala, Marc I. Diamond,
Albert A. Davis, Conrad Weihl
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2.1 Abstract
Background: Neuronal uptake and subsequent spread of proteopathic seeds, such as αS (alphasynuclein), Tau, and TDP-43, contribute to neurodegeneration. The cellular machinery
participating in this process is poorly understood. One proteinopathy associated with dominant
mutations in Valosin Containing Protein or multisystem proteinopathy (MSP) has muscle and
neuronal degeneration characterized by aggregate pathology that can include αS, Tau and TDP43.

Methods: We performed a fluorescent cell sorting based genome-wide CRISPR-Cas9 screen in
αS biosensors. αS and TDP-43 seeding activity under varied conditions was assessed using
FRET/Flow biosensor cells or immunofluorescence for phosphorylated αS or TDP-43 in primary
cultured neurons. We analyzed in vivo seeding activity by immunostaining for phosphorylated
αS following intrastriatal injection of αS seeds in control or disease mutation carrying mice.
Results: 154 genes were identified as suppressors of αS seeding. One suppressor, VCP when
chemically or genetically inhibited increased αS seeding in cells and neurons. This was not due
to an increase in αS uptake or αS protein levels. MSP-VCP mutation expression increased αS
seeding in cells and neurons. Intrastriatal injection of αS preformed fibrils (PFF) into VCP-MSP
mutation carrying mice increased 33hosphor αS expression as compared to control mice. Cells
stably expressing fluorescently tagged TDP-43 C-terminal fragment (CTF) FRET pairs generate
FRET when seeded with TDP-43 PFF but not monomeric TDP-43 (TDP-43 biosensors). VCP
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inhibition or MSP-VCP mutant expression increases TDP-43 seeding in TDP-43 biosensors.
Similarly, treatment of neurons with TDP-43 PFFs generates high molecular weight insoluble
phosphorylated TDP-43 after 5 days. This TDP-43 seed dependent increase in 34hosphor TDP43 is further augmented in MSP-VCP mutant expressing neurons.
Conclusion: Using an unbiased screen, we identified the multifunctional AAA ATPase VCP as a
suppressor of αS and TDP-43 aggregate seeding in cells and neurons. VCP facilitates the
clearance of damaged lysosomes via lysophagy. We propose that VCP’s surveillance of
permeabilized endosomes protects against the proteopathic spread of pathogenic protein
aggregates. The spread of distinct aggregate species may dictate the pleiotropic phenotypes and
pathologies in VCP associated MSP.

KEYWORDS
CRISPR screen, seeding, alpha-synuclein, TDP-43, Frontotemporal dementia
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2.2 Background
α-synuclein (αS) is the principal component of protein inclusions found in a family of
neurodegenerative disorders known as synucleinopathies . Synucleinopathies include
Parkinson’s Disease, Diffuse Lewy body disease (DLB), multiple system atrophy, and REM
sleep behavior disorder (RBD)200. αS contains an amyloid-like region making it prone to
aggregate. Several lines of evidence suggest that aggregated αS can seed the fibrillization of
soluble, monomeric αS201. This process may relate to disease pathogenesis and progression4. αS
fibrils enter neurons via endocytosis and template new αS aggregates within the cytoplasm22.
This leads to synapse loss, neurodegeneration, and ultimately the release of αS fibrils to adjacent
cells resulting in aggregate propagation along interconnected neurons 4. The cellular process of
proteopathic seeding consists of several regulated steps. These include seed uptake, vesicular
trafficking, endolysosomal escape, and templated conversion of cytosolic αS.
One route of seed uptake is endocytosis. αS seeds can enter cells and neurons via the
endocytic system. These seeds then penetrate the endolysosomal membrane facilitating their
escape into the cytoplasm1,2204. Pharmacologically blocking cellular uptake or increasing
endolysosomal membrane damage can decrease and increase seeding efficiency, respectively 204.
Previous studies have identified genetic modifiers of αS toxicity associated with its intracellular
expression in yeast or C. elegans1,2205. However, genetic modifiers of proteopathic seeding have
not been explored.
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VCP (also called p97, or cdc48 in yeast) is a ubiquitin-directed AAA-ATPase implicated in
multiple forms of neurodegeneration206. Dominantly inherited mutations in VCP cause
multisystem proteinopathy (MSP), associated with multiple variably penetrant phenotypes that
include inclusion body myopathy, frontotemporal dementia, ALS, and Parkinsonism . Just as the
phenotypes are variable, VCP patients develop varied aggregate pathologies that include αS,
TDP-43, Ta u, SQSTM1, and ubiquitin inclusions140,207–209. How VCP disease mutations lead to
cellular degeneration and protein inclusions is unclear. VCP affects the trafficking and clearance
of polyglutamine aggregates in vitro210. VCP is also necessary for both autophagic and
proteasomal degradation of ubiquitylated proteins, including TDP-43 and ER-associated proteins
via ERAD206. VCP has more recently been proposed to behave as a protein disaggregase
specifically acting upon pathologic tau aggregates140. By binding to distinct adaptors, VCP alters
its functionality, allowing it to participate in its many other functions such as ERAD, vesicular
trafficking, DNA repair, and cell cycle regulation206.
VCP disease mutations alter its association with distinct adaptors 126,211. Specifically, VCP
disease mutations have reduced binding to UBXD1 and increased interactions with Ufd1/Npl4
creating both a loss and gain of function with regard to UBXD1 and Ufd1 dependent
processes126,133,147,211. Notably, a VCP-UBXD1 dependent complex is recruited to damaged
endolysosomes133. This complex recruits the deubiquitinase YOD1, which cleaves K48 linked
ubiquitin chains from the lysosomal membrane facilitating lysophagic degradation133. VCP
inhibition, loss of UBXD1, or VCP disease mutant expression lead to a delay in the clearance of
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damaged late endosomes resulting in the accumulation of galectin-3 positive puncta in both VCP
mouse models and patient tissue 133,212.
MSP patients are pathologically characterized as a TDP-43 proteinopathy213. MSP patient
tissue accumulates aggregated and insoluble TDP-43 in affected muscle and CNS tissue213. 90%
of MSP patients have myopathy that precedes dementia by ~10 years 214. Whether TDP-43
aggregate pathology spreads from muscle to motor neuron and ultimately the cortex is unknown.
TDP-43 contains an intrinsically disordered or prion-like domain that facilitates its templated
aggregate conversion215. Like αS, TDP-43 aggregates can serve as proteopathic seeds that
propagate in cell and mouse models216,66
Functional genomic screens are a powerful tool to identify proteins participating in distinct
cellular pathways. In this study, we utilized an αS seeding FRET biosensor to screen a CRISPR
knockout library. This approach identified multiple suppressors of αS seeding, of which the
AAA ATPase, VCP, was further explored both in vitro and in vivo.
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2.3 Methods and materials
αS FRET seeding assay
Generally, HEK 293T αS-CFP/YFP is plated in a black-bottomed 96-well plate with the
density of 80k/well in DMEM media with 10% FBS and Penicillin-Streptomycin. Three control
cell lines – no-transfected HEK293T cells, αS-CFP, and αS-YFP transduced cells are cultured in
the same condition. αS PFF is sonicated and prepared with OPTIMEN and 1 µL Lipofectamine
2000 (Invitrogen) for each well and added dropwise to the cell after 48 hours. The cells are
harvested after 24 hours for flow cytometry, the same as reported. Briefly, the cells are detached
by 0.05% trypsin-EDTA (Gibco), centrifuged, then fixed with 2% PFA for 15 minutes, and
finally resuspended in MACSima Running Buffer. The samples are analyzed by MACSQuant®
VYB. FRET signal is excited by 405nm lasers and detected by 525/50 band pass filter. At the
same time, the CFP and YFP are excited by 405nm and 488nm lasers and filtered by 450/50nm
and 525/50nm, respectively. The data is analyzed with FlowJ v10 software. Each FRET signal is
calculated as the percentage of FRET-positive cell timing Median FRET fluorescence intensity
and then normalized to its vehicle control.
VCP mcherry vectors are a gift from Hemmo Meyer’s lab. The mutations were confirmed
by Sanger sequencing (GENEWIZ) with VCP plasmid primers described before. 250ng of the
plasmid is transfected with OPTIMEN and 0.5µL Fugene 6 (Promega) in each well 24 hours
after plating. The cells were then treated the same way as described above. The mcherry signal is
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excited by 561nm laser and filtered via 615/20nm, and the FRET signal is analyzed separately
for mcherry positive and negative cells.
Knockdown is achieved by reverse transfection of Human SMARTPOOL siRNA from
Dharmacon or Thermo Silencer Select siRNA. 6pmol siRNA is prepared in OPTIMEN and
0.3µL Lipofectamine™ RNAiMAX (Invitrogen) according to its protocol and added to each well
in a 96-well plate. Then 80k suspended αS-CFP/YFP cell is plated in each well already with
siRNA droplet. The αS PFF is treated 48 hours after plating as described above. The
concentration and duration of the drug treatments were summarized in supplemental Table 1.
TDP-43 FRET seeding assay
TDP-43 biosensor plasmids were designed to express the glycine-rich aggregation-prone
region of TDP-43 from amino acids 262 to 414. Gene expression was driven by a CMV
promoter in a lentiviral FM5 plasmid. At the N-terminus, an alanine codon (GCG) was added to
enhance expression, and the C-terminus was fused to a flexible 12-amino acid linker
(GGTTCTGCTGGCTCCGCTGCTGGATCCGGCGAATTC) with mClover3 or mRuby3.
Lentivirus was generated as previously described and transduced to HEK293T cells to stably
express both TDP-43 aa262-414-mClover3 and TDP-43 aa262-414 mRuby3. High-expressing
monoclonal cell lines were sorted and tested for responsiveness to TDP-43 aggregates from
TDP-43 peptides and brain homogenates from human cases with TDP-43 pathology.
TDP-43 sequence:
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ATGGCGAAGCACAATAGCAATAGACAGTTAGAAAGAAGTGGAAGATTTGGTGGTAA
TCCAGGTGGCTTTGGGAATCAGGGTGGATTTGGTAATAGCAGAGGGGGTGGAGCTG
GTTTGGGAAACAATCAAGGTAGTAATATGGGTGGTGGGATGAACTTTGGTGCGTTCA
GCATTAATCCAGCCATGATGGCTGCCGCCCAGGCAGCACTACAGAGCAGTTGGGGT
ATGATGGGCATGTTAGCCAGCCAGCAGAACCAGTCAGGCCCATCGGGTAATAACCA
AAACCAAGGCAACATGCAGAGGGAGCCAAACCAGGCCTTCGGTTCTGGAAATAACT
CTTATAGTGGCTCTAATTCTGGTGCAGCAATTGGTTGGGGATCAGCATCCAATGCAG
GGTCGGGCAGTGGTTTTAATGGAGGCTTTGGCTCAAGCATGGATTCTAAGTCTTCTG
GCTGGGGAATG.
Generally, HEK 293T TDP-43-Ruby/Clover is plated in a black-bottomed 96-well plate
with the density of 80k/well in DMEM media with 10% FBS and Penicillin-Streptomycin. Three
control cell lines – no-transfected HEK293T cells, TDP-43 Ruby, and TDP-43 Clover transduced
cells are cultured in the same condition. TDP-43 PFF is sonicated and prepared with OPTIMEN
and 1µL Lipofectamine 20000 (Invitrogen) for each well and added dropwise to the cell after 24
hours. The cells are harvested after 48 hours for flow cytometry, the same as reported. Briefly,
the cells are detached by 0.05% trypsin-EDTA (Gibco), centrifuged, then fixed with 2% PFA for
15 minutes at dark, and finally resuspended in MACSima Running Buffer. The samples are
analyzed by MACSQuant® VYB. FRET signal is excited by 488nm lasers and detected by
614/50 band pass filter. At the same time, the Clover and Ruby are excited by 488nm and 561nm
lasers and filtered by 525/50nm and 615/20nm, respectively. The data is analyzed with FlowJ
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v10 software. Each FRET signal is calculated as a percentage of FRET-positive cell timing
Median FRET fluorescence intensity and then normalized to its vehicle control.
PFF/monomer conc. &
duration
EGCG
50μM; 0-24hr
10nM; 0-24hr
Bortezomib
10nM; 0-24hr
10nM; 0-24hr
3-MA
1μM; 0-24hr
10nM; 0-24hr
Rapamycin
100nM; 0-24hr
10nM; 0-24hr
LLOME
1μM; 0-4hr
30nM; 0-4hr
NMS-873
5μM; 0-4hr
30nM; 0-4hr
CB-5083
1μM; 0-24hr
10nM; 0-24hr
Eeyarestatin I, EerI
2μM; 0-24hr
10nM; 0-24hr
Dynogo 4a
10μM; -1-24hr
10nM; 0-24hr
thapsigargin
0.3μM; 0-24hr
10nM; 0-24hr
DTT
1mM; 0-24hr
10nM; 0-24hr
Tunicamycin
2.5μg/mL; 0-24hr
10nM; 0-24hr
Table 2. 1: Drug treatments for FRET syn/TDP-43 biosensor assay
drug treatment

Drug conc. & duration

Genome-wide CRISPR-Cas9 screens on αS biosensor line
αS-CFP/YFP HEK293T cells were first transduced with WT cas9-blast. Single clones were
sorted and cultured. The new cas9 αS CFP/YFP line maintained both αS-CFP and αS-YFP and
was capable of seeding. Cas9 functions were validated by a synthetic gRNA and obtained with
99% NHEJ activity. About 50 million HEK293T syn CFP/YFP Cas9-blast cells were plated and
then infected with pooled lentivirus with Brunello gRNA library (Addgene #73178-LV) with
8ug/ml polybrene (MOI=0.3) the next day. After 24 hours, cells would undergo 1ug/ml
puromycin selection. Selected cells were replated at a density of 6.4*10^5 cell/ml after 96 hours
of selection and replaced with fresh puromycin. 2 days later, harvest 1/5 of the cell (~20 million)
(untreated group, for library representation) and seeded the rest with 10 nM αS -PFF. The seeded

41

cells were collected the same as normal αS FRET assay as described above after 24 hours and
sorted by Sony SY3200 cell sorter. DNA extraction was performed via QIAamp DNA Blood
Midi on FRET positive and negative cells, as well as unsorted cells, which were separately
amplified by PCR and deep sequenced by Illumina NovaSeq. The FRET positive and negative
groups were compared with the untreated total population group separately via Megack RRA.
For pathway enrichment, 154 hits were input to g:profiler and plot via Cytoscape as described
before.
αS, Tau and TDP-43 Fibril preparation
αS PFF and monomer are generated as described before217,218. Briefly, purified human
recombinant WT αS monomer (2 mg/ml) was incubated in 20 mM Tris-HCl, pH 8.0, 100 mM
NaCl for 72 h at 37°C with shaking at 1000 rpm in an Eppendorf Thermomixer. To determine
the concentration of fibrils, the fibril reaction mix was centrifuged at 18,000×g for 15 min to
separate fibrils from the monomer. The concentration of αS monomer in the supernatant was
determined in a BCA protein assay according to the manufacturer’s instructions, using the
bovine serum albumin (BSA) standard curve. The measured decrease in αS monomer
concentration was used to determine the concentration of fibrils in the 72 h fibril reaction
mixture. To isolate preformed fibrils (PFF) from the monomer, centrifuge the αS mix at
18,000×g for 15 min to separate fibrils from the monomer. Resuspend fibril pellet in the buffer
containing 20 mM Tris-HCl, 100 mM NaCl, pH 8.0. αS PFF was always freshly sonicated right
before seeding.
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Fluorescently labeled fibrils of αS were generated as previously described219. αS (1 mg/mL)
was dissolved in 100 mM NaHCO3, sonicated for 15 min, and spun through a 50 kD filter
(Amicon UFC5050) at 16,100 ×g for 15min. Alexa Fluor 647 NHS Ester (Thermo Fisher
A20006) was dissolved in DMSO to 10 mg/ml. Dye solution (molar ratio of dye: αS = 2.1:1) was
pipetted into monomerized αS during stirring, and the mixture was stirred on bench for ~1h. The
mixture was then loaded onto a size exclusion column (Superdex 75 10/300 GL) and eluted with
5mM NaOH. The peak containing monomeric, labeled αS was collected, aliquoted, and kept
frozen until use. For aggregation assays, αS was dissolved in 10 mM NaOH at 1 mg/mL. αS-647
was added at a 5% labeling ratio. Then the solution was sonicated for 20 minutes, filtered
through a 100 kD membrane filter (Amicon Ultra, 540655) at 16,100 × g for 15 min at 4°C. The
protein and dye concentrations were measured by absorption at 280 nm, and 647 nm,
respectively, and the labeling ratio was determined to be 4.9%. To prepare labeled αS fibrils,
monomer solution (5% α-syn-AF647) and solutions were incubated in 100 mM NaP, pH 7.4, 10
mM NaCl for 120 h aggregated in a non-binding 96-well plate (Corning, #3651) at a
concentration of 30 μM with intermittent shaking in aggregation buffer (100 mM NaP, pH 7.4,
10 mM NaCl). A 2 mm diameter glass bead was added to each well to accelerate the aggregation
through stirring. The plate was kept at 37°C and agitated by orbital shaking once every 1 minute
for 5 seconds.
Tau PFF and monomer are generated as described before242. Briefly, purified recombinant
tau monomer (300 µg/ml) was incubated in the buffer containing 20 mM Tris-HCl pH 8.0, 100
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mM NaCl, 25 µM low molecular weight heparin, 0.5 mM DTT for 48 h at 37°C with shaking at
1000 rpm in an Eppendorf Thermomixer. To determine the concentration of fibrils, the fibril
reaction mixer was centrifuged at 18,000×g for 15 min to separate fibrils from monomer. The
concentration of tau monomer in the supernatant was determined in a BCA protein assay along
with a BSA standard curve. The measured decrease in monomer concentration was used to
determine the concentration of tau fibrils in the 48 h fibril reaction mixture. Tau fibrils is
resuspended from the pellet with the same Tris buffer at desired concentration.
Recombinant TDP-43 (rTDP-43) was generated in Escherichia coli and purified as
previously described216. Briefly, rTDP-43 was bound to nickel–nitrilotriacetic acid–agarose and
washed with wash buffer 1 (50 mM Tris, pH 8.0, 500 mM NaCl, 10% glycerol, 10% sucrose, 1
mM TCEP), washed with wash buffer 2 (50 mM Tris, pH 8.0, 500 mM NaCl, 10% glycerol,
10% sucrose, 50 mM Ultrol Grade imidazole, pH 8.0, 1 mM TCEP), and finally eluted (50 mM
Tris, pH 8.0, 500 mM NaCl, 10% glycerol, 10% sucrose, 300 mM Ultrol Grade imidazole, pH
8.0, 1 mM TCEP). Then, rTDP-43 was ultracentrifuged in a Beckman Coulter Optima MAX-XP
Ultracentrifuge at 40,000 rpm for 30 min at 4 °C to remove any pre-existing aggregates. Soluble
protein was diluted to 4uM in the reaction buffer (50 mM Tris, pH 8.0, 250 mM NaCl, 5%
glycerol, 5% sucrose, 150 mM Ultrol Grade imidazole, pH 8.0, 0.5mM TCEP). rTDP-43
aggregation was started by shaking at 1,000 rpm at 22 °C for 30 min with an Eppendorf
ThermoMixer C. Samples were incubated at 22 °C and collected after one to ten days. Fulllength TDP-43 recombinant protein is produced as previously described216. To obtain the TDP44

43 monomer, TDP-43 protein was ultracentrifuge 40,000g 30 mins at 4 °C. The supernatant was
collected and freshly used.
Primary neuronal culture
WT hippocampal neurons were obtained from E17-18 mice (Charles River). Hippocampi
are dissected in calcium- and magnesium-free Hanks’ Balanced Salt solution (HBSS) and
dissociated by 0.05% Trypsin-EDTA at 37°C for 5-10 mins followed by 1% Dnase I for 2
mins220. The cells are then resuspended with plating media to the concentration of 125k/ml and
plated on Poly-D-lysine coated plates or coverslips. The media is changed to neurobasal media
(neurobasal plus + B27 + 5mM L-Glutamine) after 2-4 hours. The culture was treated with 1mM
Ara-C to inhibit the growth of glia at DIV3. The αS PFF is sonicated and added directly to the
cell at DIV10.
VCP and UBXD1 shRNA is delivered via lentivirus. Lentivirus were added to the neurons
at DIV5 with MOI≥1. For LLoMe or VCP inhibitors experiments, drug or vehicle control was
added simultaneously with αS PFF or monomer (30nM) for 4 hours. Then the media is fully
exchanged to the conditioned neurobasal media without drug and αS PFF or monomer. The
neurons were harvested at DIV15.
R155H/WT neurons were cultured from embryos from R155H/WT intercross. The
hippocampus from each embryo was dissected and cultured separately and then plated at the
same density. The genotypes were examined by PCR (Transnetyx) (Forward Primer:
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CCTCTAATTGCACTTGTATTGCTTTGT; Reverse Primer:
CTGGGATCTGTCTCTACAACTTTGA).
Immunohistochemistry
Cells were fixed in 4% PFA for 10 mins and permeabilized with 0.1% Triton X-100 in PBS
for 10 mins. Then the cells were blocked with 2% BSA in PBS at RT for 1 hour. Cells were
stained with primary antibody at 4 °C overnight, followed by three washes with PBS. Cells were
then incubated with the Alexa 488 555 or 647 tagged secondary antibody in 1:500 dilution for 1
hour at RT. The nucleus was stained with DAPI (1:1000) for 10 min at RT. After three wash
with PBS, the cells are mounted by Mowiol. Pictures were taken by Nikon Eclipse 80i
fluorescence microscope and processed via ImageJ.
The FRET images were taken under Olympus FluoView1200 confocal microscope. The
laser and band filters were set as listed:
Channel

Excitation wavelength (nm)

Band filter (nm)

αS Biosensor line
CFP

440

425-475

YFP

488

500-550

FRET

440

500-550

TDP-43 Biosensor line
Clover

488

500-550

Ruby

559

605-625

FRET

488

605-625

Immunoblot
Mouse cortex or cells are lysed in RIPA buffer with protease inhibitor cocktails (PMSF and
PIC) followed by two 30 sec on and 30 off sonication cycles at 50% power. The protein
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concentration is normalized by the BCA assay. Samples were loaded into 10 to 15% gel and
transferred into nitrocellulose or PVDF membrane. The membranes were blocked by 5% milk in
PBS-0.2% Tween20 and incubated with the primary antibody in blocking solution overnight at
4 °C degree. The membrane was then washed three times with PBS-0.2% Tween20 and
incubated with secondary goat anti- rabbit or mouse HRP antibody (1:5000) for 1 hour. Blot was
rinsed three times with PBS-0.2% Tween20 and probed by a fresh mixture of ECL reagents at
dark and then exposed by SYNGENE.
To fractionate the insoluble portion of αS, we performed sequential extraction as
described221. Briefly, neurons were first dissolved in TBS-1%Tx-100, and sonicated for ten
cycles of the 30s on, 30s off with 50% power. The lysate would incubate on ice for 30 mins. 1/10
of the lysate was saved as total protein, while the remains were ultracentrifuged 100,000g 4 °C
for 30 mins. The supernatant was collected as Tx- 100 soluble fraction. The pellet was washed
with TBS-1%Tx-100, sonicated, and ultracentrifuged. Ultimately, the pellet was resuspended
with TBS-2%SDS and sonicated for 15 cycles of 30s on, 30s off. Soluble and insoluble fraction
were run by western blot as usual. The loading amount was determined by the concentration of
total protein measured by BCA.
TPD-43 soluble and insoluble extraction is done as our previous method. Briefly, neurons
from one 35mm dish were first lysed with RIPA buffer with protease inhibitor cocktails (RIPA
buffer) on ice. The lysate was then sonicated with QSONICA sonicator for ten cycles of 30s on,
30s off with 50% power. 1/10 of the lysate was saved as total protein. The rest was
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ultracentrifuged at 100,000g 4 °C for 30 mins. The supernatant was kept as RIPA soluble
fraction. The pellet was then washed with RIPA buffer once, resonicated, and ultracentrifuged
with the same condition. The pellet was finally resuspended with the same amount of UREA
buffer (30 mM Tris, pH 8.8, 7M urea, 2M thiourea, and 4% CHAPS) as an insoluble fraction.
Soluble and insoluble fraction were run by western blot as normal. The loading amount was
determined by the concentration of total protein measured by BCA.
Animals
C57BL/6 (stock No.: 000664) and VCPR155H/WT (B6;129S-Vcptm1Itl/J, Stock No: 021968)
were purchased from Jackson Laboratory. To obtain VCP cKO (VCPR155C/FL; Rosa26CREERT2), we first crossed VCP flox;flox with Rosa26-CREERT2 (B6.129Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J , Stock No: 008463) to get VCP flox;wt; Rosa26-CREERT2.
Then we bred those mice with VCPR155C/WT reported previously for VCP cKO222. All mice
utilized in the study and breeding were on a C57BL/6 background. Both male and female mice
were used in this study. Animal procedures were performed in accordance with protocols
approved by the Animal Studies Committee at Washington University School of Medicine.
Intrastriatal injection and mouse brain harvest
Both mice are Intraperitoneal injected with 75 mg tamoxifen/kg body weight at ten weeks
of age and wait one month for gene knockdown. The R155C mutation allele and the sufficiency
of VCP flop knockdown were confirmed by PCR. The primers are listed in Appendix.
Intrastriatial injection is performed as described. αS PFF is prepared as described above and
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diluted in sterile PBS. αS PFF is sonicated 10 mins before injection. The mouse is anesthetized
and injected at the dorsal striatum (Bregma=0.2mm, midline=2.0mm, depth=-3.2mm) of the left
hemisphere. The same amount of PBS is used as vehicle control. The recovery of mice is
monitored in the following week and sacrificed after 90 days. The mouse was first
anesthetized in the Isofluorane chamber and perfused with PBS containing heparin. The whole
brains were removed from the skull and fixed in 4% PFA overnight at 4 °C degree and cut
coronally into 40micrometer sections and stored in cryoprotectant solution at 4 °C degree for
staining. Sections were first rinsed three times with TBS and then blocked with blocking solution
for 30 minutes (5% normal goat serum with 0.1% Triton X-100 in TBS). Sections were stained
with the primary antibody in TBS-0.1% Triton X-100 plus 2% normal goat serum at 4 °C
overnight, followed by three washes with TBS. Sections were then incubated with the Alexa 488
555 tagged secondary antibody in 1:1000 dilution for 2 hours at RT. The nucleus was stained
with DAPI (1:1000) for 20 min at RT. After three wash with TBS, the sections were mounted on
the glass slides. True black (cat: NC1125051) was incubated with the sections for 5 minutes to
quench the auto-fluorescence. Finally, slides were coverslipped using Prolong Gold mounting
medium. Pictures were taken by a Hamamatsu NanoZoomer or Nikon Eclipse 80i fluorescence
microscope. The images were processed, and fluorescence intensity was calculated via ImageJ.
The antibody is listed in Appendix.
Antibodies
All antibodies used in this study are listed in supplemental Table 2.
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Table 2. 2: Antibody used in the experiments.
Antibody name

manufacturer

catalog
number

clone name

WB

Alpha Tubulin

Abcam

ab52866

EP1332Y

1:1000

Alpha-synuclein
[PHOS]/phosho ser 129

Biolegend

825701

P-syn/81A

ATG5

Cell Signaling

12994

D5F5U

biotinylated Alphasynuclein [PHOS]/phosho
ser 129

Biolegend

825704

P-syn/81A

BIP/GRP78 (purified)

BD Transduction Labs

610979

Clone 40

1:1000

FK-2

Enzo

pw8810-050

UBCJ2

1:500

Galectin 3

santa cruz

sc-32790

B2C10

1:500

Galectin 8

Abcam

ab109519

GAPDH

Cell Signaling

2118

14C10

Hsp90

Abcam

13492

AC88

1:1000

LAMP1

Santa Cruz

sc-20011

H4A3

1:200

LC-3

nanoTools

0231-100

5F10

mCherry

Abcam

ab167453

NPL4

santa cruz

sc-134746

p62/SQSTM1

Proteintech

18420-1-AP

PAN 14-3-3

Santa Cruz

sc-1657

PLAA

Proteintech

12529-1-AP

syn-1

BD Transduction Labs

610787

TDP43 (TARDBP)

Proteintech

10782-2-AP

TDP43 [PHOSPHO]

Proteintech

22309-1-AP

TIA1

Santa Cruz

sc-1751

Tuj1 (beta III tubulin)

Abcam

ab18207

Tuj1 (beta III tubulin)

R&D

MAB1195

Tyrosine Hydroxylase

Millipore

ab152

UBXD1

Abcam

ab80659

UFD1

santa cruz

sc377222

VCP p97 ATPase

Fitzgerald

10R-P104A

Statistical Analysis
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IF

1:200
1:500
1:2000

1:100
1:1000

1:1000
1:1000

H-300

1:500
1:1000

H-8

1:100

1:1000
1:500

Clone 42

1:1000
1:1000
1:250

C-20

1:200
1:400

TuJ-1

1:50
1:4000
1:500

E-9

1:500
1:500

The data (except CRISPR screening) is analyzed by GraphPad Prism 9. Statistical tests
included unpaired t-test, one-way ANOVA, multiple t-test, linear interpolation (95%
confidence), and two-way ANOVA. Data were displayed as mean ± SEM. Two-stage step-up
methods of Benjamini Krieger and Yekutieli, Dunnett, Sidak correction were used to minimize
false alarm from multiple comparisons.
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2.4 Results
2. 4. 1 Genome-wide CRISPR knockout screen identifies genes protective
against αS seeding
To identify genes that regulate αS seeding, we utilized a previously described HEK293 αS
CFP/YFP biosensor cell line (αS biosensor) (Figure 2.1)101. These cells stably co-express two αS
constructs. One tagged with CFP (donor) and another with YFP (acceptor). We exogenously
applied human WT αS PFF or monomer with Lipofectamine for 24 hours to the αS biosensor
line. Only αS PFF treated, but not monomer or empty Lipofectamine treated cells, induce new
aggregation of soluble intracellular αS, as shown by CFP and YFP positive aggregates. This
PFF-dependent process is referred to as a seeding activity. Finally, those CFP/YFP positive
aggregates can be visualized by FRET under confocal microscopy (excitation = 440nm,
emission= 500-550nm) (Figure 2.1A, lower panel). Quantitation of the percent of FRET+ cells
and FRET intensity can be detected using flow cytometry (Figure 2.1B)223. The FRET efficiency,
measured as %(FRET+cells) * Median Fluorescent Intensity(MFI) (FRET+cells), was significantly higher
in αS PFF treated group as compared with Lipofectamine control and αS monomer controls
(mean= 67.55 vs. 0.96 vs. 0.30) (Figure 2.1C). In addition, αS PFF induced FRET efficiency is
sensitive and quantitative in a concentration-dependent manner (Figure 2.1D).
To perform our screen, we clonally expressed spCAS9 in the αS biosensor line and then
infected with a pooled Brunello gRNA library covering 19114 different genes/ 4 gRNA each and
1000 non-targeting controls at a low MOI (<0.3) for seven days with puromycin selection
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(Figure 2.2A). The pooled knockdown αS- spCAS9 biosensor maintained αS seeding capacity in
a concentration-dependent manner (Figure S2. 1). These biosensors were treated with 10nM αS
PFF and flow-sorted into FRET positive and FRET negative groups. DNA was isolated from
FRET positive, FRET negative, and the unseeded total cell population. Then deep sequencing
was performed to identify the guide RNAs represented in each group (Figure 2.2A). This
sequence data was analyzed via the MegaCK algorithm in both the FRET positive and negative
populations compared with untreated control. 111 genes were enriched in the FRET positive
population as compared to the total population, and 43 genes were underrepresented in the FRET
negative group versus total population (FDR<0.05 and fold change >2 or <0.5) (Figure 2.2B).
These 154 genes (red dots) were considered “protective” or suppressors of αS seeding in the
biosensor line (Figure 2.2B-C; Appendix).
The screen identified genes and pathways previously identified in other αS screens for αS
toxicity. Notably, we identified 15 genes associated with ER-Golgi-endosome trafficking. These
included VPS51 and VPS52, which are components of the Golgi-associated retrograde protein
(GARP) complex. The GARP complex interacts with PD-associated protein, LRRK2, and
deletion of either VPS51 or VPS52 homologs in yeast increases αS accumulation and toxicity224.
Other modifiers not previously identified in screens include ATP6V0B, ATP6V0C, and
ATP6V1A that encode subunits of Vacuolar-type ATPase (V-ATPase). ATP6V0B KD inhibits
autophagic degradation and increases αS aggregation225 and is downregulated in patients with αS
inclusions226. Pathway analysis identified an enrichment in genes associated with the cellular
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stress response, such as VCP, SEC61B, and KDELR1. Notably, the ER stress response is
upregulated in PD brains and correlates with αS toxicity in multiple model systems 227.
We validated nine candidate suppressors from both FRET positive and negative selections
(ATP6V0C, KDELR1, LAMTOR5, RAB35, RABAC1, SEC61B, TMEM147, VCP, and VPS51)
using siRNA knockdown in αS biosensors. Following 48 hours of siRNA treatment, αS PFF
(10nM) was added with Lipofectamine, and FRET efficiency was measured 24 hours later. Six
candidate suppressors, when knocked down, increased FRET efficiency and included ATP6V0C,
VPS51, KDELR1, SEC61B, LAMTOR5, and VCP (Figure 2.2D). To further confirm our
findings with VCP, we generated a lentiviral vector expressing a VCP specific or control gRNA,
infected spCAS9 αS biosensors for seven days and treated with αS PFF. Similar to that seen with
VCP siRNA, FRET efficiency was increased in VCP CRISPR KO αS biosensors (Figure 2.2EF).
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Figure 2. 1: αS seeding can be sensitively detected by FRET in the αS biosensor line.
(A) Representative FRET confocal microscopy images of αS biosensor line (αS CFP/YFP)
treated with Lipofectamine (left, ctrl), 10nM αS monomer (center) and αS PFF (right) after 24
hours. Scale bar= 10μm (B) Flow cytometry tracing of FRET signal from αS biosensors. FRET+
gate (CFP vs FRET) was drawn from empty Lipofectamine treated cells with no aggregation. (C)
Quantitation of integrated FRET signal from FRET-flow cytometry is calculated as % FRET+
cell * Median (FRET+ Intensity). **** p < 0.0001,n.s., no significance by one-way ANOVA.
error bars are ± S.E.M. (D) Quantitation of cells treated with increasing concentrations of αS
PFF for 24 hours. Cells are harvested after 24 hours and analyzed the same as 1C. Each dot
represents an independent experiment.
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Figure 2. 2: A genome-wide CRISPR/Cas9 screen identifies genes protective to αS seeding.
(A) αS biosensor line stably expressing spCAS9 was transduced with sgRNA lentiviral library
(Brunello). Following antibiotic selection, biosensors were seeded with αS PFF (10nM) and
flow sorted 24 hours later. Genomic DNA from positive and negative groups as well as unsorted
total population were collected and decoded by NGS. (B) Volcano plot of genes identified in the
screen. Colored in blue are all the genes plotted from FRET- group, while colored in black are
those plotted from FRET+. Red dots are protective hits from both groups (5% FDR), specifically
genes with a fold change <0.5 that were underrepresented in FRET- cells and genes >2 that were
overrepresented in the FRET+ cells. (C) Pathway analysis of 153 protective genes via
g:profiler. The enriched pathway is visualized by cytoscape. (D) Normalized FRET from αS
biosensors following siRNA knockdown of 9 genes identified in the screen and αS PFF
treatment. (n ≥9 repeats ; *** p < 0.001, ** p < 0.01 and * p < 0.05 by one-way ANOVA. error
bars are ± S.E.M.) (E) Immunoblot with anti-VCP and anti-GAPDH of cell lysates from αS
biosensors/spCas9 cells treated with a VCP gRNAs at low (L) medium (M) and high (H)
concentration and harvest at 3 and 6 days after transduction. (F) Normalized FRET of αS
biosensors/spCas9 cells treated with a VCP gRNA or scrambled control gRNA following 24hour application of αS PFF. (P = 0.0439 by a two-tailed student’s t-test). n = 4 biologically
independent FRET assay. Data presents as mean ± S.E.M.
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Figure S2. 1: spCas9-gRNA αS biosensor maintain seeding capacity.
spCas9 αS biosensor was treated with pooled library and maintained as described in Fig 2.2A,
followed by αS seeding at different concentration. After 24hours, cells are harvested and the
percentage of FRET is measured by flow cytometry
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2. 4. 2 VCP inhibition increases α-synuclein seeding efficiency
As shown in Figure 2.1, αS seeding as measured by FRET is not seen with the application
of monomeric αS101. Consistent with this, VCP siRNA treated αS biosensors showed no increase
in FRET signal when treated with αS monomer (10nM) as compared with control siRNA treated
(Figure 2.3A). Moreover, Lipofectamine is necessary for efficient FRET in this assay (“Lipo”
seeding). The application of αS PFF (10nM) directly to the media (“naked” seeding) fails to
induce robust aggregation and FRET signal after 24 and 48 hours, with less than 0.2% of cells
being FRET positive (data not shown), suggesting that Lipofectamine facilitates entry into the
endolysosomal pathway101. Notably, VCP KD did not increase “naked’ seeding and only
augmented “Lipo” seeding when compared with scrambled control KD (Figure 2.3A). To verify
αS PFF entry through the endocytic pathway with “Lipo seeding”, we pre-treated cells with
Dynogo-4a (10μM), a dynamin I/II inhibitor, for one hour before αS PFF with Lipofectamine
application for 24 hours. Consistent with previous studies showing that αS PFF internalization is
dynamin-dependent228, we found a decrease in FRET with Dynogo-4a (Figure 2. 3B).
Subsequent studies using the αS biosensor line are performed using “Lipo” seeding (Figure
2.3B-E; 2.7A).
In order to probe the role of VCP specifically at the time of endocytic entry into the cytosol,
we modified our seeding protocol to a four-hour application of αS with Lipofectamine and
subsequent washout of αS PFF from the media. Seeding activity is quantified via FRET-Flow
after 20 hours. This four-hour application was sufficient to seed αS aggregation as measured by
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FRET in a concentration-dependent manner (Figure 2.3C). A four-hour treatment at the time of
αS PFF application with the lysosomal permeabilizing agent (LLoMe, 1μM, 4hr) significantly
increased FRET (Figure 2.3D). Treatment of αS biosensors with the VCP inhibitor NMS-873229
for four hours at the time of αS PFF application similarly increased seeding efficiency as
measured by FRET (Figure 2.3D).
We further validated the effect of VCP inhibition with two additional VCP inhibitors, CB5083230 and Eeyarestatin I (Eer1)231. Continuous application of either inhibitor with αS PFF
increased the seeding efficiency as measured by FRET (Figure 2.3F). VCP inhibition has been
show to effect both the autophagic and proteasomal pathways. 24-hour application of the
proteasome inhibitor Bortezomib or autophagy modulators (100nM Rapamycin and 1μM 3methyladenine (3-MA)) with αS PFF did not affect seeding efficiency (Figure 2.3F). Finally,
both VCP inhibition and knockdown can induce ER stress and activate the unfolded protein
response (UPR)232,233. Treatment of αS biosensors with the ER stress inducing agents
dithiothreitol (DTT, 1mM, 24hr), thapsigargin (0.3μM; 24hr), and tunicamycin (2.5μg/mL, 24hr)
with αS PFF (10nM) for 24 hours had no effect or decreased FRET efficiency as compared to
vehicle controls. This suggested that the effect of VCP inhibition on seeding is ER stress
independent (Figure 2.3E). Notably, no treatment significantly altered FRET efficiency
compared with vehicle control when αS monomer was added (blue and red bars, Fig 3E),
indicating that these effects are αS PFF dependent.
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To see whether the increased seeding efficiency with VCP inhibition was due to an increase
in αS PFF uptake, we employed a fluorescently conjugated αS PFF (αS-PFF 647). αS-PFF 647
retains seeding capacity in αS biosensors (Figure S2.2). Four-hour αS biosensor treatment with
αS-PFF 647 in the presence of LLoMe or NMS-873 did not increase the amount of internalized
αS PFF 647, as quantified by the percentage of Alexa 647 positive cells via flow cytometry
(Figure 2.4A-B). Uptake was also unchanged when comparing scrambled and VCP siRNA KD
cells (Figure 2.4C). In contrast, the dynamin I/II inhibitor Dynogo-4a significantly decreased αS
PFF 647 uptake when measured at 4 hours post seed application (Figure 2.4D). In addition, the
increased seeding efficiency with VCP chemical inhibition or VCP siRNA knockdown was not
due to an increase in the steady-state levels of soluble αS, as determined by immunoblot against
total αS and αS fluorescence intensity as measured by CFP median fluorescent intensity via flow
cytometry (Figure 2.4E-K). Notably, VCP siRNA KD was >75% and a four hour treatment with
NMS-873 was sufficient to increase the level of high molecular weight (HMW) ubiquitin
conjugates consistent with VCP inhibition (Figure 2.4E-H).
To explore the role of VCP in a more relevant system of αS seeding that does not require
the use of the carrier Lipofectamine, we adapted a previously described assay that adds αS PFF
to primary cultured hippocampal neurons (HNs)23. Previous studies show that exogenously
applied αS PFF can induce endogenous αS aggregates in HNs that are hyperphosphorylated and
Tx-100 insoluble. To avoid continuous αS PFF application, we added αS PFF to the media of
HNs for only four hours, followed by washout with conditioned media. A four hour application
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of αS PFF versus αS monomer was sufficient to generate detergent-insoluble, high molecular
weight αS, and phospho-αS after five days, shown by fractionation immunoblot or via
immunofluorescence using a phospho-αS (phospho Ser129/81A) antibody in HNs (Figure 2.5AB). This four-hour treatment allows us to manipulate the effect of VCP inhibition at the time of
seed uptake. We then co-treated HNs with LLoMe (1uM) and αS PFF (1μg/ml) for 4 hours
followed by washout, which further increased the amount of phospho-αS as compared with the
application of αS PFF and vehicle (Ethanol) after five days (Figure 2.4C-D). These results were
αS PFF dependent since treating HNs with LLoMe, and monomeric αS (1μg/ml) failed to
generate phospho-αS aggregates (Figure 2.4C). We performed a similar assay and treated HNs
for four hours with the reversible VCP inhibitor ML240234(100nM) and αS PFF (1μg/ml).
Notably, the application of ML240 for four hours at the time of αS PFF application increased the
level of phospho-αS as compared with vehicle-treated control, while ML240-treated HNs with
αS monomers show no phospho-αS signal (Figure 2.4E-F). We further validated the role of VCP
with two different shRNAs against VCP. Primary HNs were treated with lentiviral shRNA (at
DIV5) for five days prior to a five-day continuous application of αS PFF or monomer treatment
(at DIV10). Both VCP shRNAs decreased VCP protein levels and demonstrated an increase in
an αS PFF-dependent increase in phospho-αS staining compared with scrambled shRNA control
(Figure 2.6). Treatment with LLoMe, ML240, or shRNA-VCP treatment did not alter cell
viability as measured by MTT assay after 10 and 15 days in culture (Figure S2. 3).
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Several studies support that αS PFFs enter the endocytic pathway and permeabilize the late
endosome resulting in seed escape to the cytoplasm235,236. Once damaged, cytosolic galectins
(e.g., Gal3 and Gal8) bind to exposed intraluminal carbohydrates tagging the permeabilized late
endosome. This damaged galectin-positive late endosomes are then cleared via lysophagy.
Indeed treatment of U20S cells with “naked” αS PFF-647 for four hours demonstrates
internalized αS PFF in Gal8 and Lamp1 positive structures (Figure S2.4E). Blocking the
lysophagic clearance of Gal8 puncta with bafilomycin increases the number of cells with
damaged late endosomes with αS PFF treatment (Figure S2.4A-B). This increase returns to
baseline following removal of bafilomycin and αS PFF from the media (Figure S2.4C-D).
Furthermore, Gal8 positive puncta were retained in VCP knockdown cells (Figure S2.4F-G).
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Figure 2. 3: VCP inhibition enhances αS seeding.
(A) αS biosensors were treated with scrambled control siRNA or VCP siRNA for 48 hours prior
the application of αS monomer or PFF (10nM) with or without Lipofectamine and measured for
FRET efficiency at 24 and/or 48 hours. N=4 for each groups. ; n.s.= no significant, **** p <
0.0001 by two-way ANOVA compared with scramble siRNA in each conditions. Error bars are ±
S.E.M.). (B) αS biosensors were treated with Dynogo 4a for one hour prior to αS PFF or
monomer (10nM) treatment with Lipofectamine. n =12 repeats for PFF treated conditions. ****
p < 0.0001; n.s. for monomer treated pairs by two-way ANOVA. (C) αS biosensors treated with
αS PFF for 4 hours followed by media exchange and washout. FRET signal was measured the
same as in 3A, 20 hours after washout. n.s. no significant and **** p < 0.0001 compared to
vehicle washout at different concentrations. Each dot represents an independent experiment. (D)
Normalized FRET of αS biosensors co-treated with αS monomer or PFF (30nM) with the
indicated chemical compound or vehicle for four hours followed by washout and FRET
measurement 20 hours later. (n =14 repeats for each PFF treated conditions; n.s. for all monomer
treated pairs; **** p < 0.0001 by two-way ANOVA in some PFF treated pairs as indicated. error
bars are ± S.E.M.). (E) Normalized FRET of αS biosensors co-treated with αS monomer or PFF
(10nM) with the indicated chemical compound or vehicle for 24 hours. FRET signal was
obtained same as 3A (n ≥8 repeats for each PFF treated conditions; n.s. for all monomer treated
pairs; **** p < 0.0001 and * p < 0.05 by two-way ANOVA in some PFF treated pairs as
indicated. error bars are ± S.E.M.).
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Figure 2. 4: VCP inhibition does not affect seed uptake or αS protein levels.
(A) Quantification of percentage of Alexa- 647 positive cells (seed uptake) from αS biosensors
co-treated with Alexa-647 tagged αS PFF together with vehicle or NMS-873 (1µM) for 4 hours.
n=3 biological repeat. Data is Mean ± S.E.M. n.s. no significant from student’s t test (B)
Quantification of seed uptake from αS biosensors co-treated with Alexa-647 tagged αS PFF and
LLoMe or vehicle for 4 hours. n=3 biological repeat. Data is mean ± S.E.M. n.s. no significant
from student’s t test. (C) Quantification of seed uptake from VCP or scramble siRNA treated
cells with 4-hour Alexa-647 tagged αS PFF application. n=4 biological repeat. Data is mean ±
S.E.M. n.s. no significant from student’s t test. (D) Quantification of seed uptake from αS
biosensors treated with Dynogo-4a or DMSO for one hour and then Alexa-647 tagged αS PFF
for four hours. n=4 biological repeat. Data is mean ± S.E.M. ****p < 0.0001 from student’s t
test. (E) Immunoblot of anti-Ubiquitin (FK-2), and total α-synuclein (syn-1) from αS biosensors
treated for four-hours with NMS-873 (5µM) or DMSO. α-tubulin and HSP90 are loading
controls. (F) Quantitation of band intensities of VCP and α-synuclein in E. *** p < 0.001 and
n.s.=no significant by two-way ANOVA. (G) Immunoblot of anti-VCP, and α-synuclein (syn-1)
from αS biosensors treated with scrambled or VCP siRNA for 48 and 72 hours. GAPDH and
HSP90 are loading controls. (H) Quantitation of band intensities of VCP and α-synuclein in G.
** p < 0.01 *** p < 0.001 and n.s.=no significant by two-way ANOVA. (I) Quantification of
CFP fluorescent intensity of NMS-873 treated cells. Drug treatment and timeline were the same
as 3D. n=3 biological repeat. Data is mean ± S.E.M n.s. no significant from student’s t test. (J)
Quantification of CFP fluorescent intensity of LLoMe treated cells. Drug treatment and timeline
were the same as 3D. n=3 biological repeat. Data is mean ± S.E.M. n.s. no significant from
student’s t test. (K) CFP fluorescent intensity of αS biosensors treated with scrambled or VCP
siRNA. n=4 biological repeat. Data is mean ± S.E.M.
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Figure 2. 5: VCP inhibition enhances αS seeding in neurons.
(A) Immunofluorescence for phospho-αS and Tuj1 (neurite marker) in HNs treated for 4 hours
with αS PFF or monomer (1μg/ml) followed by washout and harvest 5 days later. (B)
Immunoblot for αS from detergent soluble and insoluble lysates of HNs treated for 4 hours with
αS PFF or monomer (1μg/ml) and then harvested 5 days later. Note that the 2%SDS insoluble
fraction has high molecular weight αS positive multimers. PAN 14-3-3 is the loading control.
(C) Immunofluorescence for phospho-αS and Tuj1 in HNs co-treated with αS PFF or monomer
(1μg/ml) and LLoMe (1uM) or vehicle for 4 hours. Immunostaining was performed after 5 days.
Scale bar =20μm. (D) Quantitation of phospho-αS/Tuj1 staining as in 3C. Quantitation in 3C and
subsequent HN studies were performed using the average intensity of multiple fields from
individual coverslips. Each coverslip was treated as an independent experiment. n=6 for ethanol
and LLoMe groups respectively. Experiments were repeated from 3 different cultures. **p <
0.01 by student’s t-test. Error bars are ± S.E.M. (E) Immunofluorescence for phospho-αS and
Tuj1 in HNs co-treated with αS PFF or monomer (1μg/ml) and ML240 (100nM) or DMSO
control for 4 hours and harvested after 5 days. Scale bar =20μm (F) Quantitation of phosphoαS/Tuj1 staining as in 3D. n=6 for DMSO and ML240 group. Experiments were repeated from 3
different cultures. *p < 0.05 by student’s t-test. Error bars are ± S.E.M.).
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Figure 2. 6: VCP knockdown enhances αS seeding in neurons.
(A) Immunofluorescence for phospho-αS and Tuj1 in HNs infected with lentiviral vectors
expressing scrambled or one of two different shRNAs targeting VCP for 5 days and then treated
with αS PFF or monomer (1μg/ml) for 5 days. Scale bar =20μm (B) Quantitation of phosphoαS/Tuj1 staining as in 3F. Experiments were repeated from 3 different cultures. N=7,5 and 5 for
scramble and VCP shRNA 1 and 2 respectively. **p < 0.01 one-way ANOVA with Dunnett
correction. Error bars are ± S.E.M. (C) Representative immunoblot from independent HN lysates
treated with scramble or VCP shRNAs for anti-VCP and GAPDH. (D) Quantitation of band
intensities of VCP over GAPDH control.
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Figure S2. 2: αS biosensor shows seeding activities in a concentration dependent manner.
Alexa647 tagged αS PFF show moderate seeding capacity according to FRET assay.
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Figure S2. 3: Cell viability in HNs with treatment.
(A) HNs are treated with LLoMe (1uM) or ML240 (100nM) for 4 hours at DIV10. Cell are
tested by MTT assay right after the temporal treatment (DIV10) or at the time we harvest the cell
for staining (DIV15). (B) HNs are transduced with lentivirus shRNA targeting genes as indicated
at DIV4 (MOI=10). Cell viabilities are tested by MTT assay at DIV10 and DIV15 respectively.
p<0.05 and n.s. = no significant by one-way ANOVA.
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Figure S2. 4: αS fibrils induce reversible endolysosomal damages.
(A) U2OS cells are treated αS PFF (100nM) with or without BafA1 (100nM). Cells are harvested
after 24hrs and stained by Galectin-8. Cells with only BafA1 is considered as baseline control.
(B) Quantification of images in A. αS PFF treated Cells with more than 3 Gal8 puncta are
counted, and normalized by number of nucleus (DAPI) in a double-blind analysis. (C) U2OS
cells treated αS PFF and BafA1 (100nM) for 4 hours and chased for indicated time. (D)
Quantification of images in C. (E) Co-localization of exogenous Alexa647 tagged αS PFF
(100nM) after 24hours with LAMP1 and Gal8. (F) U2OS cells with VCP siRNA KD or
scramble are treated with BafA1 (100nM) and αS PFF (100nM). Cells are harvested after 24hrs
and stained by Galectin-8. (G) Quantification of images in F.
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2. 4. 3 VCP disease mutations increase αS seeding both in vitro
VCP disease mutations affect a subset of VCP dependent cellular processes such as
endocytic trafficking, nutrient sensing, autophagosome maturation, and, more recently,
lysophagy133,206. This is due to an impairment in VCP mutant association with the adaptor
UBXD1235. We performed siRNA knockdown of VCP and the VCP adaptors UFD1, NPL4,
UBXD1, and PLAA and the autophagy proteins ATG5 and SQSTM1 along with a scrambled
control in αS biosensors (Figure S 2.4A). Following 48 hours of knockdown, αS biosensors were
treated with αS PFF or monomer (10nM), and FRET was measured 24 hours later. Knockdown
of the VCP adaptor UBXD1 significantly increased FRET efficiency compared with scramble
siRNA control, whereas application of monomeric αS did not alter the FRET signal (Figure
2.7A). To confirm UBXD1 is an essential VCP cofactor for seeding, we knocked down UBXD1
using shRNA in primary HNs five days prior to αS PFF application. UBXD1 KD also increased
phospho-αS staining compared with scrambled shRNA control (Figure 2.7B-D). The increase in
phospho-αS staining was not associated with a minor change in cell viability that was measured
by MTT assay after 10 (1.08 vs. 0.92 0, p= 0.0329) and 15 days (p= >0.9999) in culture (Figure
S2.3).
To understand if VCP disease mutations augment αS seeding activity, we first evaluated αS
seeding in the setting of mutant VCP overexpression. αS biosensors were transfected with
mCherry-tagged VCP-WT or one of three different mCherry-tagged VCP disease mutations
(R95G, R155H, and A232E) for 24 hours then treated with αS PFF (10nM) and quantified for
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FRET efficiency 24 hours later. Transfected cells are selected for mCherry signal via flow
cytometry simultaneously with FRET. Whereas cells not expressing mCherry were unchanged
and cells expressed similarly level of tagged VCP(Figure 2.8A and S2.5B). To evaluate this in
primary HNs, we transduced neurons with lentiviral constructs (CCIV) expressing wild-type
VCP-myc or one of two different VCP disease mutations (VCPR155H-myc and VCPA232E-myc) or
empty vector (CCIV), five days prior to αS PFF application. Lysates from similarly treated HNs
demonstrated comparable levels of myc-tagged VCP-WT or mutant expression. Following five
days, VCP-R155H and VCP-A232E expressing neuronal cultures had an increase in phospho-αS
staining compared with control and VCP-WT expressing cultures (Figure 2.8B-D).
In order to explore αS PFF seeding in a non-overexpressed neuronal system, we cultured
primary HNs from VCPWT/WT and VCPRH/WT embryos, treated them with αS PFF, and then
immunostained for phospho-αS five days later. VCP-R155H mutation knockin mice have been
previously generated and characterized . VCPRH/WT HNs had a significant increase in phospho-αS
staining compared with VCPWT/WT HNs controls (Figure 2.8E-F). Notably, the phospho-αS
staining in VCPRH/WT treated HNs was less filamentous and predominantly perinuclear compared
to VCPWT/WT HNs. The perinuclear phospho-αS aggregates co-localized with p62/SQSTM1 and
LAMP1 suggesting an alteration in aggregate trafficking (Figure 2.8G).
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Figure 2. 7: VCP cofactor UBXD1 knockdown augments αS seeding.
(A) αS biosensors were treated with scrambled control siRNA or siRNAs targeting the indicated
genes for 48 hours prior to the application of αS PFF or monomer (10nM) and harvested for
FRET efficiency at 24 hours. n =4 and 12 for the monomer and PFF treated group respectively
for each KD. Adjusted p ****p < 0.0001 for UBXD1 by two-way ANOVA with Šidák
correction n.s. = no significance. Error bars are ± S.E.M. (B) Immunofluorescence for phosphoαS and Tuj1 in HNs infected with lentiviral vectors expressing scrambled or a shRNA targeting
UBXD1 for 5 days and then treated with αS PFF or monomer (1μg/ml) for 5 days Scale bar
=20μm. (C) Quantitation of phospho-αS/Tuj1 staining from PFF treated HNs infected with
scramble or control UBXD1 shRNAs. Experiments were repeated from 3 different cultures. N= 5
for each groups.. * p<0.05 by Student’s t test). (D) Representative immunoblot from HN lysates
treated with scramble or UBXD1 shRNAs for anti-UBXD1 and α-tubulin

78

79

Figure 2. 8: VCP disease mutation expression enhances αS seeding.
(A) αS biosensors were transfected with plasmids expressing VCP-WT, or one of three disease
mutations (R95G, R155H and A232E) fused to an mcherry tag for 24 hours and then treated with
αS PFF (10nM). FRET efficiency is quantified in mCherry+ and mCherry- cells separately and
all normalized to VCP-WT (n=11 repeats for each group. ***p < 0.001; ****p < 0.0001; ns, no
significance; two-way ANOVA with Dunnett’s correction) (B) Immunofluorescence for
phospho-αS and Tuj1 in HNs treated with empty control lentiviral vector, VCP-WT-myc or one
of two myc tagged VCP disease mutations (R155H or A232E). HNs were transduced with
lentivirus as indicated for 5 days before 10nM αS PFF treatment. HNs were harvested after
another 5 days. Scale bar =20μm. (C) Quantitation of phospho-αS/Tuj1 staining as in 8C.
Experiments were repeated from 3 different cultures. *p < 0.05; ****p < 0.0001; ns, no
significance compared with the VCP-WT group by one-way ANOVA. (D) Immunoblot of
lysates from HNs overexpressing lentiviruses expressing empty vector, VCP-WT-myc, VCPR155H-myc or VCP-A232E-myc using an anti-myc antibody or pan 14-3-3 as a loading control.
(E) Immunofluorescence for phospho-αS and Tuj1 in HNs from wild-type mice or mice carrying
a VCP-R155H knock-in allele (VCPR155H/WT) treated with αS PFF (1μg/ml) for 5 days. (F)
Quantitation of phospho-αS/Tuj1 staining as in 8F. Neurons came from 10 and 15 independent
cultures from WT and VCPR155H/WT embryos. Outlier is removed by ROUT method, Q=1%,
followed by Student’s t test. p<0.0001), Scale bar =20μm. (G) Immunofluorescence of WT or
VCPR155H/WT HNs treated with αS PFF (1μg/ml) and harvested 5 days later with anti-phospho-αS
(red) and p62 (green) (upper panels) or anti-phospho-αS (red) LAMP1 (green) (lower panels).
Scale bar =10μm.
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Figure S2. 5: Gene knockdown efficiency and VCP vector transfection.
(A) αS biosensor is reverse transfected with siRNA (6pmol). Cell lysis are saved at 48 and 72
hours after transfection. Immunoblot is performed on each KD for protein level change. (B)
Immunoblot with anti-mCherry of αS biosensor lysate with overexpression of different VCP
vectors.
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2. 4. 4 VCP disease mutations increase αS seeding in vivo
We next examined the effect of pathogenic VCP mutations on αS seeding in vivo.
VCPRH/WT mice display no neuronal loss, TDP-43 inclusions, or pathologic features consistent
with autophago-lysosomal dysfunction up to 13 months old145. To explore an additional VCP
mouse model that only expresses a VCP disease mutant allele, we also used a mouse line that
deletes the VCP-WT allele and only allows expression of a single VCP-R155C mutant allele
following tamoxifen treatment (VCPRC/FL; Rosa26-Cre ERT2 (cVCP-RC) (Figure 2.S5). Similar
to our previous study, lysates from the cortex of VCPRH/WT mice have no changes in the levels of
autophagic proteins (Sequestosome-1/p62), ER stress (BiP/GRP78), or ubiquitinated proteins
(Figure 2.S5B-C)145. Following five days i.p. tamoxifen treatment, cortical lysates from cVCPRC mice have a 41% reduction in total VCP protein level but no changes in autophagic levels
(Sequestosome-1/p62), ER stress (BIP/GRP78), or ubiquitinated proteins (Figure 2.S5B-C).
However, high molecular weight ubiquitinated proteins, and SQSTM1 levels increase with age,
as demonstrated by immunoblot of cortical lysates at six months after tamoxifen, supporting that
VCP dysfunction is present (Figure 2.S5D-E). We have previously demonstrated that an increase
in Gal3 levels occurs early, before autophagic dysfunction in VCP RH/WT mouse muscle212.
Similar to skeletal muscle, Gal3 and LAMP1 levels are increased in both VCP RH/WT and cVCPRC mouse cortical lysates suggesting an accumulation of damaged late endosomes (Figure
2.S5B-C)133,212.
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We injected 5ug αS PFF or PBS into the striatum of 4-month-old C57 control, VCPRH/WT, or
cVCP-RC mice and harvested the brain after three months (Figure 2.9A). Age-matched untreated
control, VCPRH/WT, cVCP-RC, C57 mice, or mice treated with PBS had no phospho-αS staining
in any brain regions (Figure 2.9A-E). In contrast, C57 control mice injected with αS PFF had a
significant increase of phospho-αS in multiple brain regions (Figure 2.9A-E). We found
phospho-αS staining was significantly increased in the anterior and posterior cortices of
VCPRH/WT, and cVCP-RC injected with αS PFF compared with that of C57 (Figure 2.9A-E).
Other brain regions such as the amygdala and substantia nigra trended toward an increase in
phospho-αS staining but did not reach statistical significance (Figure 2.9F-G).
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Figure 2. 9: VCP disease mutations enhance αS seeding in vivo.
(A) Drawing of coronal sections through mouse brains. Shaded regions indicate areas utilized for
quantitation and boxes denote regions corresponding to images in B and D. (B) Representative
immunofluorescence images with pSer129-syn antibody of anterior cortices from C57, cVCPR155C, and VCPR155H/WT mice injected unilaterally into the striatum with 5ug αS PFF after 90
days. 4 month aged C57 (n=10), VCP R155H/WT (n=5) and VCP R155C/FL; Rosa26-Cre ERT2
(cVCP-R155C) (n=5). Scale bar=25 μm. (C) Quantitation of the percentage of p-syn in entire
anterior cortices (* P<0.05 by student’s t-test). (D) Representative immunofluorescence images
with pSer129-syn antibody of posterior cortices from C57, cVCP-R155C, and VCPR155H/WT mice
as described in A. scale bar=25 μm. (E) Quantitation of the percentage of p-syn in posterior
cortices (* P<0.05, **P<0.01(* P<0.05 by student’s t-test). (F-G) Quantitation of p-syn in
Amygdala and substantia Nigra. (* P<0.05, ns, no significance student’s t-test)
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Figure S2. 6: VCP disease mutant mice accumulate Galectin-3.
(A) Genotyping of cVCP-R155C mice. Cortical tissues from 4-month-old cVCP-R155C and C57
are genotyped. cVCP-R155C mice are i.p. injected with Tamoxifen in 5 continuous day and
harvested after one month for genotyping. (B) Representative immunoblot for VCP, p62, pan 143-3, BiP/GRP78, Lamp1, Galectin-3, HSP90, and ubiquitin (FK2) from cortical brain lysates of
4-month-old C57 (n=3), VCPR155H/WT (n=4) and cVCP-R155C (n=4) mice. In the case of cVCPR155C mice, they are intraperitoneally injected with tamoxifen at 90 days of age and the brain
was collected after one month. (C) Quantification of band intensities of VCP, p62, Bip/GRP78,
LC3, FK2, Lamp1 and Gal3. (D) Representative immunoblot for VCP, p62, 14-3-3, Lamp1,
Galectin-3, and ubiquitin (FK2) from cortical brain lysates of cVCP-R155C mice following one
month or six months of i.p. tamoxifen treatment. (E) Quantitation of band intensities of VCP,
p62, Lamp1, FK2 and Gal3 (n=3 for both groups, multiple t test, p=0.001516, n.s.= no
significance).

87

2.4.5 VCP disease mutations enhance other proteopathic seeding
A subset of VCP patients have Parkinsonism and post-mortem evidence of αS pathology.
However, most VCP patients have TDP-43 inclusions in the CNS and muscle207–209. To evaluate
the role of VCP in the seeding of TDP-43, we utilized a HEK TDP-43 FRET biosensor that
expresses both a Clover tagged-TDP-43 CTF and Ruby tagged-TDP-43 C-Terminal Fragment
(CTF) (aa 262-414) (TDP biosensors). Exogenously applied preformed fibrillar TDP-43 (TDP43 PFF 50nM) with Lipofectamine, but not monomeric TDP-43 (50nM), recruited the
aggregation of soluble intracellular TDP-43 CTF after 48 hours. This resulted in Clover and
Ruby positive aggregation as visualized by fluorescence (Figure 2.10A). Similar to the αS
biosensor line, these TDP-43 PFF-dependent aggregates can also be detected by FRET under
confocal microscopy (excitation=488nM and emission=605-625nM) (Figure 2.10A). Cells with
FRET were quantified using a Clover vs. FRET plot with flow cytometry and selected against
empty Lipofectamine treated control with no aggregates (black polygon gates in Figure 2.10B).
FRET efficiency is calculated as a percentage (FRET positive cell)* MFI (FRET positive cell)223. The TDP-43
FRET signal is TDP-43 PFF-dependent since little signal was captured in monomer and empty
Lipofectamine treated groups (Figure 2.10A-C). In addition, this FRET signal is sensitive and
quantitative in a concentration-dependent manner (Figure 2.10D). To biochemically confirm that
the FRET signal corresponded to TDP-43 CTF aggregation, we analyzed the cell lysates by
fractionation immunoblot. An anti-GFP antibody was used to detect Clover- and Ruby-tagged
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TDP-43 CTF (~40kDa). Only TDP-43 PFF treated TDP biosensor lines generated detergentinsoluble and high molecular weight TDP-43 CTFs (Figure 2.10E).
As with αS-biosensors, co-application of the VCP inhibitor NMS-873 (5uM) for four hours
at the time of seed application (50 and 100nM) to TDP biosensors followed by washout
significantly increased FRET as compared with DMSO treated control cells two days later
(Figure 2.10F). This phenomenon is seed-dependent since NMS-873 failed to increase FRET in
TDP-43 biosensors when TDP-43 monomer treatment was used. To explore the role of VCP
disease mutations on TDP-43 seeding, we transfected TDP biosensors with myc tagged-VCPWT or one of two different VCP disease mutations (R155H and A232E) for 24 hours, followed
by TDP-43 PFF application. Cells expressing either VCP disease mutants exhibited an increase
in FRET efficiency 48 hours later compared with VCP-WT control (Figure 2.10G & S2.7).
Meanwhile, a recent studies demonstrated an VCP disease mutation in Alzheimer patients
(D395G) increase tau seeding efficiency140. The similar effect was showed in tau seeding with
mcherry tagged VCP- R95G, R155H and A232E (Figure S 2.8).
To further explore the effect of TDP-43 seeding in a more relevant system, we developed a
TDP-43 seeding assay in primary hippocampal neurons. The addition of TDP-43 PFF (10nM) to
HNs resulted in the appearance of phosphorylated TDP-43 Ser409/410 (pTDP) positive puncta in
TDP-43 PFF treated group (Figure 2.11A; S2.9). Fractionation of lysates from HNs one or five
days post-treatment with buffer, monomeric TDP-43 (10nM), or TDP-43 PFF (10nM) and
subsequent immunoblot for TDP-43 revealed an increase in high molecular weight TDP-43 in
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the RIPA insoluble fraction of TDP-43 PFF treated HNs (Figure 2.11B). The pTDP staining was
not present immediately after the addition of TDP-43 PFF since no increase in pTDP above that
seen prior to seed application. In contrast there was a significant increase in pTDP staining when
TDP-43 PFF treated HNs were stained after 5 days (Figure 2.11C). Moreover, the amount of
pTDP staining post-TDP-43 PFF treatment correlated with the concentration of TDP-43 PFF
seed used. In addition, TDP-43 PFF induced cytosolic pTDP-43 puncta co-localized with TIA1
and p62/SQSTM1 similar to pathologic TDP-43 inclusions in patients (Figure 2.11E)237. As seen
with VCP mutant expression in TDP-43 biosensors, treatment of primary HNs from VCPWT/WT
and VCPRH/WT embryos with TDP-43 PFF (10 nM) revealed an increase pTDP-43 puncta in
VCPRH/WT HNs compared with VCPWT/WT HNs (Figure 2.11F-G).
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Figure 2. 10: VCP inhibition or VCP disease mutations enhance TDP-43 seeding in cells.
(A) Representative FRET confocal microscopy images of TDP-43 biosensor line (TDP-43
Clover/Ruby) treated with empty Lipofectamine (left, ctrl), 50nM TDP-43 monomer (middle)
and 50nM TDP-43 PFF (right) after 48 hours. Scale bar= 10μm (B) Tracing of FRET signal via
flow cytometry. FRET+ gate (Clover vs FRET) was drawn from empty Lipofectamine treated
cells with no aggregation. (C) Quantitation of integrated FRET signal is measured by % FRET+
cell * Median Fluorescent Intensity (FRET+ cells). **** p < 0.0001,n.s., no significance by oneway ANOVA. Error bars are ± S.E.M. (D) Graph of FRET efficiency from TDP-43 biosensors
were treated with TDP-43 PFF at different concentration and harvested after 48 hours (each dot
represents triplicates in each condition). (E) Immunoblot for TDP-43 CTF (anti-GFP) from
detergent soluble and insoluble lysates of TDP-43 biosensor cells treated with TDP-43 monomer
or PFF and then harvested after 48 hours. Note that the RIPA insoluble fraction accumulated
high molecular weight TDP-43 positive multimers. GAPDH is a loading control. (F) Normalized
FRET from TDP-43 biosensors co-treated with TDP-43 monomer or PFF and NMS-873 (5μm)
or DMSO vehicle control for four hours followed by washout. Cells were harvested at 48 hours
after the treatment, and analyzed the same as 10C. FRET signal is normalized to DMSO 100nM
PFF treated group. (n>4 repeats for each group. ****p < 0.0001;n.s. no significance, two-way
ANOVA with Šidák correction) (G) TDP-43 biosensors were transfected with plasmids
expressing VCP-WT, or one of two disease mutations (R155H and A232E) for 24 hours and then
treated with TDP-43 PFF (10nM) for 48 hours. FRET efficiency is all normalized by VCPWT.
(n=9 repeats for each group. *p < 0.05, **p < 0.01; ****p < 0.0001; one-way ANOVA with
Dunnett’s correction)
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Figure 2. 11: VCP disease mutations increase TDP-43 seeding in neurons.
(A) Immunofluorescent staining for pTDP-43 (red), Tuj1 (green), and nuclei (blue) in primary
hippocampal neurons treated with 10nM TDP-43 monomer or 10nM TDP-43 PFF for 5 days.
Scare bar= 10μm (B) Immunoblot for TDP-43 from detergent soluble and insoluble lysates of
HNs treated with 10nM TDP-43 monomer or 10 nM PFF and then harvested after 1 or 5 days.
Note that the RIPA insoluble fraction has high molecular weight TDP-43 positive multimers. 143-3 is a loading control. (C) Quantitation of area of pTDP-43 immunofluorescence in HNs after
4 hours or 5 days after 10nM TDP-43 PFF treatment. (D) Quantitation of area of pTDP-43
immunofluorescence treated with the indicated concentrations of TDP-43 PFF and harvested at 5
days. (E) Immunofluorescent images for pTDP-43, SQSTM1, and TIA-1 from neurons treated
with TDP-43 monomer or TDP-43 PFF for five days. Scare bar= 10 μm. (F)
Immunofluorescence for phospho-TDP-43 (red) and Tuj1 (green) in HNs from wild-type mice or
mice carrying a VCP-R155H knockin allele (VCPR155H/WT) treated with TDP-43 for PFF for
5 days. (Scare bar= 20μm). (G) Quantitation of phospho-TDP/Tuj1 staining (Neurons coming
from 3 and 4 independent cultures from WT and VCPR155H/WT embryos. Outlier is removed by
ROUT method, Q=1%, followed by Student’s t test. n=4, WT and VCPR155H/WT group
respectively. *p<0.05.)
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Figure S2. 7: Immunoblot of VCP overexpression in TDP biosensor line.
Immunoblot of lysates from TDP biosensor overexpressing empty vector, VCP-WT-myc, VCPR155H-myc or VCP-A232E-myc using an anti-myc antibody or GAPDH as a loading control.
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Figure S2. 8: VCP disease mutations elevate Tau seeding.
Tau biosensors were transfected with plasmids expressing VCP-WT, or one of three disease
mutations (R95G, R155H and A232E) fused to a mcherry tag for 24 hours and then treated with
tau PFF (2nM). FRET efficiency is quantified in mCherry+ and mCherry- cells separately and all
normalized to VCP-WT (n=11 repeats for each group. ***p < 0.001; ****p < 0.0001; ns, no
significance; two-way ANOVA with Dunnett’s correction)
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Figure S2. 9: pTDP-43 is TDP-43 PFF specific in hippocampal neurons.
10nM TDP4-43 monomer, TDP-43 PFF or αS PFF is added to DIV10 HNs as indicated. After 5
days, HNs are harvested and stained with both (p)TDP-43 and (p)syn(81A).
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2.5 Discussion
Functional genomic screens utilizing CRISPR knockout approaches are an invaluable tool
to elucidate proteins related to distinct cellular pathways. Here, we employed a CRISPR wholegenome KO screen to identify modifiers of αS seeding using an αS biosensor cell line. αS
seeding spans many cellular processes that include endocytic uptake, vesicular trafficking,
templated aggregate conversion, and protein degradation by both the proteasome and autophagy.
Our screen identified proteins associated with vesicular trafficking between the ER, Golgi and
endosome, and the cellular stress response. Notably, these pathways have been identified as
modifiers of αS toxicity and stability in yeast and cell models238,239. Vesicular trafficking may
have been particularly enriched since our screen and the αS biosensor cell line required αS PFFs
to be applied with the carrier, Lipofectamine, as a means of facilitating endocytic uptake.
Our further studies expanded upon the role of VCP in αS seeding. VCP is a multifunctional
protein necessary for many ubiquitin-dependent processes, including protein degradation, vesicle
trafficking, cell division, and organelle clearance206. Recently, we identified a role for VCP in
recognition of permeabilized late endosomes and their subsequent lysophagic degradation 133.
Endocytosed proteopathic seeds such as αS and Tau enter the cytoplasm, where templated
aggregate conversion of soluble monomer occurs by damaging the endosomal
membrane133,240,241. The fate of permeabilized late endosomes depends upon the degree of
membrane damage. For example, some damaged endosomes are rapidly repaired by ESCRT
proteins242. In contrast, endosomes damaged beyond repair are tagged by intracellular galectins
98

such as galectin-3133. Galectin positive endosomes recruit the ubiquitin ligase, Trim16, which
ubiquitinates endosomal membrane proteins243. Notably, only lysine-63 linked ubiquitin chains
on the endosome surface are targeted for lysophagy133. VCP, in association with UBXD1,
PLAA, and the deubiquitinase YOD1 recognize and cleave lysine-48 linked ubiquitin chains on
damaged late endosomes, leaving lysine-63 linked ubiquitin chains allowing lysophagic
degradation133. Loss of VCP or VCP disease mutant expression leads to the persistence of
galectin-3 positive damaged late endosomes in cells, mouse models, and patient tissue133,212.
A previous genomic screen using a Tau biosensor line identified several components of the
ESCRT machinery as suppressors of Tau seeding244. Our screen identified VCP and Trim16 as
suppressors of αS seeding. Further experiments found that knockdown of the VCP adaptor,
UBXD1 that is necessary for lysophagy, and VCP disease mutations defective in lysophagy also
increase αS seeding. One distinction between these two screens is the use of Lipofectamine to
facilitate entry into the endocytic pathway of αS. Lipofectamine is known to damage endosomal
membranes and may allow αS to generate larger “holes” that are not repaired by ESCRTS 242.
However, VCP’s role in seeding was not exclusively Lipofectamine dependent since VCP
inhibition, knockdown, or VCP mutant expression facilitated “naked” αS PFF seeding in HNs
and in vivo.
VCP disease mutations cause multisystem proteinopathy (MSP)245. MSP is a late-onset
degenerative disorder with varied phenotypes and pathologies. These include inclusion body
myopathy, ALS, and FTD213. While the predominant aggregate pathology in the brain is reported
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to be TDP-43, several studies support the identification of αS positive aggregates in the
brain207,208,246. Indeed, ~5% of MSP patients have coincident Parkinsonism214. Notably, two
recently identified families with a VCP-D395G mutation were found to have distinctive tau
pathology leading to the description of a vacuolar tauopathy in the CNS 140. Aggregate pathology
in the skeletal muscle can be varied and include TDP-43, hnRNPA1/A2B1, SQSTM1, βamyloid, desmin, and VCP74,247,248

Weakness typically precedes the onset of neurodegenerative

features such as dementia by ten years suggesting that pathology begins in peripheral tissue such
as skeletal muscle214. Whether protein aggregates from skeletal can seed the aggregate process in
motor neurons or cortical neurons, remain speculative. It is noteworthy that mice carrying the
D395G missense mutation in VCP had an increase in Tau seeding, supporting that VCP disease
mutations can facilitate the propagation of different aggregate species214.
TDP-43 inclusions are a prominent feature in affected VCP disease tissue 74,208. Our data
further support that TDP-43 PFF similar to αS-PFF can seed pathologic TDP-43 inclusions in
HNs. TDP-43 seeding in HNs recapitulates several features of TDP-43 pathology such as
phosphorylation, cytoplasmic redistribution, and co-localization with stress granule markers and
SQSTM1249. VCP disease mutation expression increases seeding associated pathologic TDP-43
inclusions as measured by increased phospho-TDP-43 immunostaining in HNs. This process is
TDP-43 PFF dependent since monomeric TDP-43 fails to have the same effect. Whether the
accumulation of TDP-43 inclusions is also affected by an additional role for VCP in stress
granule clearance remains to be determined158.
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Halting or mitigating the pathologic spread of protein inclusions in neurodegenerative disorders
such as Parkinson’s disease, ALS and fronto-temporal dementia has potential therapeutic
implications. Our study identifies a VCP dependent endocytic pathway that suppresses the
proteopathic spread of αS in vivo and TDP-43 in vitro. Future studies aimed at defining the
molecular components and mechanism related to VCP associated aggregate seeding may lead to
therapies targeting multiple proteinopathies and degenerative diseases.
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Chapter 3 Discussion and future direction
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3.1 protective role of VCP in protopathic seeding
NDDs become more predominant as we step into an aging society. The early symptoms of
NDDs are confusing with normal aging. Therefore, blocking the disease progression is an
attractive alternative. Proteopathic inclusion is a hallmark of NDDs, and its spreading can
correspond to neuronal loss and function loss. Because of that, it is important to understand the
mechanism of proteopathic seeding.

In this dissertation, we demonstrated the role of VCP in proteopathic seeding. In
intracellular αS seeding, VCP inhibition or knockdown or VCP disease mutations can enhance
seeding efficiency in αS biosensors and hippocampal neurons. This effect is independent of
VCP's established roles in ER stress, autophagy, the ubiquitin-proteasome system, and αS fibril
uptake or expression. Previous studies suggested that αS fibril is mainly taken up by the
endosome and merges into the lysosome for degradation. However, about half αS fibril
integrated cannot be cleaned after 24 hours250. This implied that the classical lysosomal pathway
is insufficient for αS fibril degradation. Jiang et al., and Flavin et al., found that the fibril but not
oligomer or monomer form of αS can permeabilize the endolysosome membrane, marked by
galectin protein240,251. Here, we demonstrated that VCP inhibition could aggravate the
endolysosome integrity. Our lab previously characterized VCP on lyosophagic degradation of
permeabilized late endosomes. In this work, enhancing lysosomal membrane permeability with
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the small molecule, LLoMe, or inhibiting VCP dependent-lysosome surveillance with UBXD1
knockdown or expression of VCP disease mutations also increases αS seeding.

We propose VCP mediated αS seeding via lysopahgy, a conserved mechanism when cells
are challenged by large molecules or pathogen invasion. Upon αS fibril uptake, αS fibril will
accumulate at the endolysosome vesicle. Some αS fibrils will be degraded via lysosome. At the
same time, some might damage the endolysosome and escape to the cytoplasm, where the αS
fibril will recruit αS monomers and template new fibril formation. This seeding process is
deleterious to the cell. However, the damaged endolysosome can be labeled by galectin protein
and recruit VCP and its cofactors UBXD1, which modulate damaged endolysosome to
autophagy degradation. In contrast, VCP mutations, with reduced binding to UBXD1, showed
impaired lysosphagy, failed to clean up αS fibril embedding damaged endolysosome, and, in
turn, have higher seeding efficiency.

This study also suggested a unified model of proteopathic seeding mediated by VCP.
Although the distinct inclusion is a pathological hallmark for NDDs, emerging evidence suggests
the interconnection between proteopathic seeding. For example, TDP-43 inclusions are identified
in a wide range of NDDs3 and myopathy252; APOE4 has been a genetic risk factor for Aβ
pathology (AD and DLB) for a long time. However, recent studies by Davis et al., and Zhao et
al., show that APOE4 has a detrimental effect on synucleinopathy and motor performance
independent of Aβ and tau pathology253,254. VCP mutations can also cause different types of
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NDDs, containing TDP-43, αS, or tau inclusions exclusively. This evidence indicates a shared
pathway in proteopathic seeding. Our works demonstrate that VCP mutations similarly affect αS,
tau, and TDP-43 seeding, further supporting it. Both tau and TDP-43 fibril can also be taken up
by endocytosis. Tau fibril can also induce endolysosome damage, facilitating tau seeding in
vitro241. This VCP mediated lysophagy might share in common for proteopathic seeding in
general. To test this hypothesis, we can conduct a genomic-wide screen or a targeted screen on
the seeding of other proteopathic proteins like tau and TDP-43for lysophagy components.

Besides, VCP mutations also impair mitochondria function and morphology152,153. VCPUBXD1 responds to mitophagy when mitochondria are disordered. Mitochondria dysfunction is
strongly associated with Parkinson's disease, and αS PFF is preferentially bound to the
mitochondrial membrane and destroys its respiration function255. Although no current evidence
supports mitochondria dysfunction towards seeding, we cannot exclude other mechanisms that
might take place simultaneously.
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Figure 3. 1: a proposed model of VCP roles on seeding
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3.2 New modifiers and pathways in α-synuclein seeding
In this dissertation, we used CRISPR KO screening to identify gene modifiers for αS
seeding. Even though some screens had been done on α-synuclein, we are the first group to look
at αS seeding. Our subsequent work focus on VCP, one of the genes cause of MSP1. However,
there are other genes and pathways that might be important. First, to further support our
hypothesis, we can test other lysophagy genes in our list, such as TRIM16. TRIM16 might have
a dual function in seeding. On the one hand, TRIM16 binds to galectin-3 upon damaged
endolysosome, adds autophagy targeted tag K63, and promotes lysophagy by interacting with
autophagy factors ULK1, beclin-1, and ATG16L243. On the other hand, TRIM16 can interact
with NRF2 and SQSTM1 and assist aggregates degradation via autophagy256. Furthermore, a
recent study that used lysosome immunoprecipitation and proximity assays followed by mass
spectrometry identified protein possibly participating in lysophagy after LLOMe treatment257.
Seven genes in our αS seeding hits (ATP6V1A, ATP6V1G1, NAPA, UBE2C, YKT6,
LAMTOR5, and NPC2) might also involve in lysophagy and exhibit a similar effect as VCP.

Of note, vesicle and membrane trafficking pathway is enriched in αS induced toxicity
screens on yeast172,173. Particularly, in a C elegans screening, a homolog of vesicle trafficking
genes VPS41 and SEC22 was identified, modifying αS aggregation in the worm and protecting
DA neurons loss. In our screen, vesicle transport and trafficking are enriched. For example,
VPS51 and another hit VPS52 are components of GARP/EARP complexes, which play a role in
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endosome cargo sorting and retrograde transport to trans-Golgi. Loss-of-function mutations of
VPS51 can lead to a rare neurological disorder258. We can further test the effect of those
trafficking genes in our screen on seeding by traditional neuronal culture or on propagation via
microfluidic devices. Beyond that, we validated hits ATP6V0C, KDELR1, LAMTOR5, and
SEC61B suggested novel pathways, including ER stress response, might contribute to αS
seeding, which has not been documented.

Furthermore, 35 out of 154 hits from the primary CRISPR KO screen are druggable at
different degrees, leading to > 100 different drug candidates. For example, Acetaminophen, a
drug target to co-chaperone PTGES3, decreases αS oligomerization and alleviates dopaminergic
neurons loss in worm PD models259,260. Insofar, the effect of those druggable hits should be
validated and followed by a drug screen to find a therapeutic target for αS.
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Figure 3. 2: identified druggable genes from primary hits.
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3.3 TDP-43 seeding in ALS-FTD
In this dissertation, we illustrated two TDP-43 seeding models in vitro. Compared with the
existing TDP-43 model, The TDP-43 biosensor is more sensitive, quantitively, and seeding
specific. Our data further support that similar to αS-PFF, TDP-43 PFF can seed pathologic TDP43 inclusions in HNs. TDP-43 seeding in HNs phenocopies several features of TDP-43
pathology such as hyperphosphorylation, cytoplasmic redistribution, and co-localization with
stress granule markers and SQSTM1249. Lastly, this work demonstrates the effect of VCP on
TDP-43 seeding. VCP disease mutation expression increases seeding associated pathologic TDP43 inclusions in both TDP-43 biosensor and HNs.

A future application is to test the TDP-43 seeding capacity of variants in TDP-43 positive
FTD-ALS, including GRN, TMEM106B, CHMP2B, UBQLN2, OPTN, MATR3,
hnRNPA1/A2b1, TBK1, ATXN2, UBQLN2, SQSTM1, etc. Many gene variants are linked with
TDP-43 inclusion or solubility, but their effect on TDP-43 seeding has not been characterized.
Double knockdown of CHMP2A and CHMP2B showed increasing tau seeding activities 261.
OPTN and SQSTM1 are both autophagy receptors262; UBQLN2 promotes proteasome
degradation of polyubiquitinated proteins262 and recently found to play a role in autophagy as
well263. The seeding essay can help us to understand the mechanism of TDP-43 pathology in
those patients.
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Furthermore, TDP biosensor lines may apply to diagnosis. This line is at least 250 more
sensitive than commercial TDP-43 ELISA kits. TDP-43 can be secreted extracellularly via
exosome47,264. The plasma TDP-43 level is significantly higher in FTD-TDP groups than that in
AD and healthy control. The finding in CSF is ambiguous. Although one group showed a
comparable level of TDP-43 of FTD-TDP, FTD-tau in CSF265, most studies suggested the CSF
TDP-43 level raised in ALS and FTD-TDP patients compared with either healthy control or
TDP-43 negative NDDs266. TDP-43 level in CSF is also correlated with ALS patients' survival
time267. This discrepancy may be due to the detection methods and different sub-types of
patients. Moreover, incubating ALS-FTD CSF with cells induced cytoplasmic TDP-43
aggregates after 21 days, suggesting the existence of TDP-43 seeds in those fluids47. Hence, the
seeding capable TDP-43 may be used as a diagnostic biomarker or prognosis for TDP-43
pathologies.

In addition, those TDP-43 seeding platform allows us to perform other assays, including
CRISPR genomic widescreen on TDP-43 seeding, microRNA arrays, or bulk RNA sequencing.
TDP-43 contains two RRMs and selectively regulate more than hundreds of mRNA and
microRNA level. Particularly, selective miRNAs are dysregulated in ALS patients with TDP-43
inclusion268,269. We found that rescue mir-34a, a spinal cord neuronal enriched microRNA that
decreased in ALS patients, in the TDP-43 biosensor line significantly decreased seeding
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efficiency. Given the reversible effect, small size, and abundant miRNA targets, understanding
the TDP-43 seeding modifiers will help us discover new clinical targets for TDP-43 pathology.

3.4 peripheral seeding of TDP-43
MSP can affect multiple tissues, including muscle, bone, and nervous system. In VCP
patients, myopathy is usually the first call, which onset precedes FTD-ALS (it happens) about 13
years on average, even though in some cases FTD-ALS can occur independently270. This clinical
data agrees with VCP mouse models, including ours, in which muscles developed MSP-like
phenotypes and accumulated insoluble TDP-43 prior to brain dysfunction236. Additionally,
protein aggregate is a common feature of multiple myopathies, and some proteins like desmin
own prion-like properties. Muscles, excised in our daily life, are more exposed and susceptible to
injury and environmental stress. A recent study found TDP-43 accumulated as amyloid in myogranule when muscle regenerates after injury271. Additionally, this aggregation is more frequent
in muscles with VCP mutation272. One future direction is to test if TDP-43 inclusion from
patients' muscle seeding is capable of seeding. If so, are they behave the same as the one in
CNS?

Finally, whether TDP-43 can spread within the muscle or from muscle to the brain has not
been proven in cell or mouse models. Although no evidence showed it happened with TDP-43,
peripheral seeding is observed in other proteopathic seeds. The prions can spread from different
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peripheral routes to the brains in prion diseases273. Intraperitoneal administration of Aβ-rich
brain extracts to young APP mice can induce β-amyloidosis in the cortices, although less
efficient and more delayed than direction intracerebral injection274. Although αS is most
abundant in the brain, αS is found in the plasma and CSF of patients and healthy control. Several
clinical studies found αS inclusion in peripheral tissues such as stomach, colon, and rectum in
PD patient275, and αS fibril can retrogradely transport via the vagal nerve to the dorsal motor
nucleus in the brainstem276. Either intramuscular (from hind-leg muscle or gut muscle wall),
intravenous or intraperitoneal injection of αS fibril could induce phosphorylated αS aggregates in
the brains, bring to PD like symptoms, such as loss of dopaminergic neurons, motor, and
cognitive deficits, even though those seedings are slower and less efficient than intracerebral
injection277–279.

To test the TDP-43 peripheral seeding hypothesis, we can inject seeding capable TDP-43
fibril or brain lysate into the skeletal muscles at one leg, harvest both muscle, spinal cord, and
brain at different time points, and test the transmission and seeding event retrogradely in TDP-43
transgenic mice.
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Appendix Table. Protective genes for αS seeding
Group
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+

Gene ID
SLC27A2
IFI44L
YAP1
UBE2C
HPSE
KIF1C
PDPN
LYPLA1
HNRNPA0
LAMTOR5
SUGT1
RBPMS
CAMKK2
OS9
LRRC41
KDELR1
CELF1
ZNHIT1
PPIH
RABAC1

FDR
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118

log2(Fold
change)
4.3772
4.3532
4.2783
4.241
3.9899
3.7946
3.7181
3.6877
3.6485
3.6003
3.5984
3.5688
3.5165
3.4672
3.419
3.3573
3.3333
3.2808
3.2753
3.2625

Group
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
FRET+
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Gene ID
HIBADH
TRIM16
NEK6
TOMM34
NPC2
COL4A1
STK25
POSTN
C1D
PAPOLA
NCOA2
RAB35
HSPH1
TXNRD2
DBF4
STIP1
IVNS1ABP
SIVA1
PDE10A
MAP3K2

FDR
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118
0.000118

log2(Fold
change)
3.2511
3.1945
3.1487
3.1085
3.0687
3.0495
3.0438
3.0277
2.9735
2.9589
2.9439
2.9415
2.8891
2.8644
2.8321
2.8143
2.7742
2.7282
2.7021
2.602

Group
FRET+
FRET+
FRET+
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Gene ID
IFI44
PIAS3
C11orf58
SPAG5
CARM1
GIPC1
VAT1
LMAN2
ARPP19
VAV3
MALT1
CIB1
EHMT1
PRSS21
PIM2
CAP1
PRDX3
SEC61B
USP19
DDX17
PLK2
GCN1L1
MGEA5
ECI2
TNFSF13B

FDR
0.000118
0.000323
0.000323
0.000323
0.000323
0.000505
0.000505
0.000505
0.00081
0.00081
0.00081
0.00081
0.00081
0.00081
0.000972
0.001129
0.001238
0.001238
0.001238
0.001357
0.001357
0.00147
0.00147
0.001575
0.001575

log2(Fold
change)
2.5343
3.2893
3.11
2.609
2.5799
3.2611
3.055
2.9969
3.1388
3.0517
3.0023
2.722
2.6874
2.1081
2.6236
2.9592
3.5197
2.9665
2.8722
2.9398
2.8197
3.3654
3.3354
2.8595
2.4859

Group
Gene ID
FRET+
PRSS23
FRET+
METAP2
FRET+
TRIM38
FRET+
PDIA5
FRET+
ANP32B
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PRDX4
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KDELR2
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FRET+
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EBP
FRET+
YIF1A
FRET+
STAMBP
FRET+
DNAJB4
FRET+
ERP29
FRET+
SH2B2
FRET+ HNRNPUL1
FRET+
PTGES3
FRET+
FAM3C
FRET+
SLC27A5
FRET+
FERMT2
FRET+
TACC2
FRET+
TMED10
FRET+
AHSA1
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FDR
0.001674
0.001674
0.001794
0.001909
0.001967
0.001967
0.001967
0.002019
0.002019
0.002019
0.00225
0.002475
0.002569
0.002628
0.002628
0.002717
0.002863
0.003359
0.004252
0.004432
0.00495
0.005457
0.005729
0.005886
0.006365

log2(Fold
change)
2.9191
2.9024
2.7015
2.887
2.9086
2.854
2.6154
2.8607
2.6986
2.6318
2.548
2.4016
2.6953
2.9476
1.9888
2.5051
2.4624
2.202
2.132
2.3308
2.5831
2.7082
2.1163
2.7171
3.1307

Group
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Gene ID
CIB2
LILRB4
RRAGA
TAB1
SSSCA1
HMGN4
TIMM17A
SLC35A1
TGOLN2
EHMT2
MERTK
PPP1R13L
TACC3
SMAD5
ADGRL2
CBX1
LRTOMT
C7orf34
KLHDC7A
MORC2
TCERG1
PRC1
PSMD14
ATP6V0C
TRAPPC11

FDR
0.006403
0.006867
0.008058
0.008286
0.014078
0.014599
0.014599
0.015452
0.017277
0.018675
0.021292
0.023562
0.027298
0.02975
0.032155
0.032866
0.035562
0.036319
0.036616
0.04177
0.047095
0.001238
0.001238
0.001238
0.001238

log2(Fold
change)
2.4944
2.1038
2.8375
2.8946
2.0017
2.8039
2.7675
2.4395
2.0313
2.414
1.7698
2.7847
2.1942
1.9546
2.1509
2.5533
2.1702
1.4542
1.7663
2.1945
2.2514
-2.8323
-2.3874
-2.2861
-1.9267

Group
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Gene ID
AURKB
RPL23A
GINS4
TUBGCP3
VPS52
SNRNP35
PRIM1
ATP6V0B
ACTL6A
CCT7
MCM5
BUB3
CDC45
ATP6V1A
MCM7
ARCN1
RPF2
TUT1
CDCA8
NAPA
RPL19
RPS6
SMU1
SNRPG
SNRPD2

FDR
0.002122
0.002122
0.002122
0.00275
0.00275
0.00495
0.005304
0.005304
0.005304
0.013531
0.013923
0.016599
0.018152
0.018152
0.018152
0.019127
0.019156
0.019208
0.019208
0.024181
0.024386
0.024576
0.027073
0.027073
0.027073

log2(Fold
change)
-2.3266
-1.9353
-1.213
-1.8507
-1.4399
-1.1493
-1.581
-1.3902
-1.0426
-1.903
-1.468
-1.8184
-2.4996
-1.5073
-1.3744
-1.5577
-1.3106
-1.9006
-1.1978
-2.0421
-1.5775
-1.5797
-1.9513
-1.6738
-1.5715

Group
FRETFRETFRETFRETFRETFRETFRET-

Gene ID
HAUS8
VPS51
VCP
TRRAP
PRPF19
ASH2L
UTP6

FDR
0.030354
0.030354
0.030354
0.030354
0.030354
0.030354
0.0344

log2(Fold
change)
-2.1828
-1.694
-1.6651
-1.6237
-1.3478
-1.2235
-1.2987

Group
FRETFRETFRETFRETFRETFRETFRET-
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Gene ID
RPS3A
RACGAP1
USE1
CNOT1
ATP6V1G1
TRAPPC3
YKT6

FDR
0.042381
0.044201
0.044892
0.045483
0.049
0.049886
0.049886

log2(Fold
change)
-1.4925
-1.4768
-1.1336
-1.0822
-1.4845
-1.7526
-1.615

